SELECTED BIBLIOGRAPHY

Books

  1. Achilladelis, Basil, Ralph Landau, and Alexander Scriabine. Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press, 1999.
  2. Adomakoh, C. C. Advances in the Drug Therapy of Mental Illness. Geneva, Switzerland: World Health Organization, 1976.
  3. Alwood, Edward. Dark Days in the Newsroom: McCarthyism Aimed at the Press. Philadelphia, PA: Temple University Press, 2007.
  4. The Anatomy of Sleep. Nutley, NJ: Roche Laboratories, 1966.
  5. Anderson, Oscar E., Jr. The Health of a Nation: Harvey W. Wiley and the Fight for Pure Food. Chicago: University of Chicago Press,1958.
  6. Angell, Marcia. The Truth about the Drug Companies: How They Deceive Us and What to Do About It. Melbourne, Australia: Scribe, 2006.
  7. Anxiety and Allergy. Nutley, NJ: Roche, 1966.
  8. Bate, Roger. Phake: The Deadly World of Falsified and Substandard Medicines. Washington, DC: AEI Press, 2014.
  9. Bernstein, Walter. Inside Out: A Memory of a Black List. New York: Alfred A. Knopf, 1996.
  10. Blaser, Martin J. Missing Microbes: How the Overuse of Antibiotics Is Fueling Our Modern Plagues. New York: Henry Holt and Company, 2014.
  11. Blum, Deborah. The Poison Squad: One Chemist’s Single-Minded Crusade for Food Safety at the Turn of the Twentieth Century. New York: Penguin Press, 2018.
  12. Bobst, Elmer Holmes. Bobst: The Autobiography of a Pharmaceutical Pioneer. New York: D. McKay, 1974.
  13. Bowden, Mary Ellen, Amy Beth Crow, and Tracy Sullivan. Pharmaceutical Achievers. Philadelphia, PA: Chemical Heritage Press, 2003.
  14. Braithwaite, John. Corporate Crime in the Pharmaceutical Industry. New York: Routledge, 2013.
  15. Breggin, Peter Roger. Medication Madness: A Psychiatrist Exposed the Dangerous Moon-Altering Medications. New York: St. Martin’s Press, 2008.
  16. Brody, Howard. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham, MD: Rowman & Littlefield, 2008.
  17. Carpenter, Daniel P. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press, 2010.
  18. Castagnoli, William. Medicine Avenue: The Story of Medical Advertising in America. Huntington, NY: Medical Advertising Hall of Fame, 1999.
  19. Clark, Ronald. The Life of Ernst Chain: Penicillin and Beyond. Originally published in London: Weidenfeld & Nicolson Limited, 1985; Kindle edition by Bloomsbury Press, 2011.
  20. Clark, Roscoe Collins. Three Score Years and Ten, A Narrative of the First Seventy Years of Eli Lilly and Company, 1876–1946. New York: Lakeside Press, R. R. Donnelly & Sons, 1946.
  21. Collins, James C., and Jerry I. Porras. Built to Last: Successful Habits of Visionary Companies. New York: HarperCollins, 2009.
  22. Coney, Sandra. The Menopause Industry: A Guide to Medicine’s “Discovery” of the Mid-Life Woman. London: The Women’s Press, 1995.
  23. Coppin, Clayton A., and Jack High. The Politics of Purity: Harvey Washington Wiley and the Origins of Federal Food Policy. Ann Arbor, MI: The University of Michigan Press, 1999.
  24. Crawford, Dorothy H. Virus Hunt: The Search for the Origin of HIV/AIDS. Oxford, UK: Oxford University Press, 2015.
  25. Crunden, Robert M. Ministers of Reform: The Progressives’ Achievement in American Civilization 1889–1920. New York: Basic Books, 1982.
  26. Daemmrich, Arthur A. Pharmacopolitics: Drug Regulation in the United States and Germany. Chapel Hill, NC: The University of North Carolina Press, 2004.
  27. Dowbiggin, Ian Robert. The Quest for Mental Health: A Tale of Science, Medicine, Scandal, Sorrow, and Mass Society. New York: Cambridge University Press, 2011.
  28. Dupree, Hunter A. Science in the Federal Government: A History of Policies and Activities to 1940. Cambridge, MA: Belknap Press of Harvard University Press, 1957.
  29. Dutfield, Graham. Intellectual Property Rights and the Life Sciences Industry, 2nd ed. Singapore: World Scientific Publishing, 2009.
  30. Eban, Katherine. Bottle of Lies: The Inside Story of the Generic Drug Boom. New York: Ecco, 2019.
  31. England, Paul. Intellectual Property in the Life Sciences: A Global Guide to Rights and Their Applications. London: Globe Law and Business, 2015.
  32. Espejo, Roman. The Pharmaceutical Industry: Opposing Viewpoints. Detroit: Greenhaven Press, 2012.
  33. Florey, Howard, et al. Antibiotics: A Survey of Penicillin, Streptomycin, and Other Antimicrobial Substances from Fungi, Actinomycetes, Bacteria, and Plants, vols. 1 and 2. London: Oxford University Press, 1949.
  34. Fumento, Michael. The Myth of Heterosexual AIDS. New York: New Republic/Basic Books, 1993.
  35. Galambos, Louis, Roy P. Vagelos, Michael S. Brown, and Joseph L. Goldstein. Values and Visions: A Merck Century. Whitehouse Station, NJ: Merck & Co., 1991.
  36. Gambardella, Alfonso. Science and Innovation: The US Pharmaceutical Industry during the 1980s. Cambridge, UK: Cambridge University Press, 1995.
  37. Gamble, Vanessa Northington. Making a Place for Ourselves: The Black Hospital Movement, 1920–1945. New York: Oxford University Press, 1995.
  38. Garrett, Laurie. The Coming Plague: Newly Emerging Diseases in a World Out of Balance. London: Penguin Books, 1996.
  39. Goldacre, Ben. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. New York: Farrar, Straus & Giroux, 2013.
  40. Gøtzsche, Peter C., Richard Smith, and Drummond Rennie. Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare. London: Radcliffe Publishing, 2013.
  41. Greene, Jeremy A. Generic: The Unbranding of Modern Medicine. Baltimore, MD: Johns Hopkins University Press, 2014.
  42. Greenwood, David. Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford, UK: Oxford University Press, 2008.
  43. Gross, Michael. Rogues’ Gallery: The Secret Story of the Lust, Lies, Greed, and Betrayal That Made the Metropolitan Museum of Art. New York: Random House, 2009.
  44. Hare, Ronald. The Birth of Penicillin. Sydney, Australia: Allen & Unwin, 1970.
  45. Harris, Richard. The Real Voice. New York: Macmillan, 1964.
  46. Harris, Richard F. Rigor Mortis: How Sloppy Science Creates Worthless Cures, Crushes Hope, and Wastes Billions. New York: Basic Books, 2018.
  47. Harrison, Joanne K., and Grant Harrison. The Life and Times of Irvine Garland Penn. Philadelphia, PA: Xlibris, 2000.
  48. Hawthorne, Fran. Inside the FDA: The Business and Policies Behind the Drugs We Take and Food We Eat. New York: John Wiley & Sons, 2015.
  49. ———. The Merck Druggernaut: The Inside Story of a Pharmaceutical Giant. Hoboken, NJ: John Wiley & Sons, 2003.
  50. Hayes, J. N. Epidemics and Pandemics: Their Impacts on Human History. Santa Barbara, CA: ABC-CLIO, 2005.
  51. Healy, David. Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression. New York: New York University Press, 2006.
  52. Herzberg, David L. Happy Pills in America: From Miltown to Prozac. Baltimore, MD: Johns Hopkins University Press, 2008.
  53. Higby, Gregory J., and Elaine C. Stroud. The Inside Story of Medicines: A Symposium. Madison, WI: American Institute of the History of Pharmacy, 1997.
  54. Hooper, Edward. The River: A Journey to the Source of HIV and AIDS. Boston, MA: Back Bay Books, 2000.
  55. Hoving, Thomas. Making the Mummies Dance: Inside the Metropolitan Museum of Art. New York: Simon & Schuster, 1994.
  56. Kang, Lydia, and Nate Pedersen. Quackery: A Brief History of the Worst Ways to Cure Everything. New York: Workman Publishing, 2017.
  57. Kefauver, Estes, and Irene Till. In a Few Hands: Monopoly Power in America. New York: Pantheon, 1965.
  58. Kinsella, James. Covering the Plague AIDS and the American Media. New Brunswick, NJ: Rutgers University Press, 1990.
  59. Kleinman, Daniel Lee. Politics on the Endless Frontier: Postwar Research Policy in the United States. Durham, NC: Duke University Press, 1995.
  60. Kleinman, Daniel Lee, Abby J. Kinchy, and Jo Handelsman. Controversies in Science and Technology. Madison, WI: University of Wisconsin Press, 2005.
  61. Kolata, Gina. Flu: The Story of the Great Influenza Pandemic of 1918 and the Search for the Virus That Caused It. New York: Farrar, Straus & Giroux, 1999.
  62. Law, Jacky. Big Pharma: Exposing the Global Healthcare Agenda. New York: Avalon Publishing Group, 2006.
  63. Lax, Eric. The Mold in Dr. Florey’s Coat: The Story of the Penicillin Miracle. New York: Henry Holt, 2005.
  64. Le Fanu, James. The Rise and Fall of Modern Medicine. New York: Carroll & Graf Publishers, 1999.
  65. Lesch, John E. The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine. Oxford, UK: Oxford University Press, 2007.
  66. Li, Jie Jack. Laughing Gas, Viagra, and Lipitor: The Human Stories Behind the Drugs We Use. New York: Oxford University Press, 2006.
  67. Liebenau, J. Medical Science and Medical Industry: The Formation of the American Pharmaceutical Industry. London: Palgrave Macmillan, 1987.
  68. Long, Edward V. The Intruders: The Invasion of Privacy by Government and Industry. New York: Frederick A. Praeger, 1967.
  69. Lutze, Marietta. Who Can Know the Other?: A Traveler in Search of Home. No. 29 of 225 copies. Lunenburg, Vermont: Marietta Lutze Sackler, 1997; reprint 2002. Author viewed edition in the Special Collections of Dartmouth Library, Rauner Presses Collection, control number: ocm80453625.
  70. Macy, Beth. Dopesick: Dealers, Doctors, and the Drug Company That Addicted America. New York: Back Bay Books, 2019.
  71. Maeder, Thomas. Adverse Reactions. New York: William Morrow and Company, 1994.
  72. Marks, Lara. Sexual Chemistry: A History of the Contraceptive Pill. New Haven, CT: Yale University Press, 2010.
  73. Marshall, Walter Gore. Through America; or, Nine Months in the United States. London: S. Low, Marston, Searle & Rivington, 1881.
  74. Martí-Ibáñez, Félix. The Epic of Medicine. New York: Bramhall House, 1962.
  75. ———. Journey around Myself: Impressions and Tales of Travels around the World: Japan, Hong Kong, Macao, Bangkok, Angkor, Lebanon. New York: Potter, 1966.
  76. May, Elaine Tyler. America and the Pill: A History of Promise, Peril, and Liberation. New York: Basic Books, 2010.
  77. McGreal, Chris. American Overdose: The Opioid Tragedy in Three Acts. New York: Public Affairs, 2018.
  78. Meier, Barry. Pain Killer: A Wonder Drug’s Trail of Addiction and Death. New York: Rodale Books, 2003; updated edition, Pain Killer: An Empire of Deceit and the Origin of America’s Opioid Crisis. New York: Random House, 2018.
  79. Meyer, Karl E., and Shareen Blair Brysac. The China Collectors: America’s Century-Long Hunt for Asian Art Treasures. New York: St. Martin’s Press, 2015.
  80. Meyers, Morton A. Happy Accidents: Serendipity in Major Medical Breakthroughs in the Twentieth Century. New York: Skyhorse Publishing, Inc., 2011.
  81. Mez-Mangold, Lydia. A History of Drugs. Basel, Switzerland: Hoffmann-La Roche, 1989.
  82. Mines, Samuel. Pfizer: An Informal History. New York: Pfizer, 1978.
  83. Moynihan, Ray, and Alan Cassels. Selling Sickness: How the World’s Biggest Pharmaceutical Companies Are Turning Us All into Patients. New York: Nation Books, 2006.
  84. Nesi, Thomas J. Poison Pills: The Untold Story of the Vioxx Drug Scandal. New York: St. Martin’s Press, 2008.
  85. Offit, Paul A. The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis. Hartford, CT: Yale University Press, 2007.
  86. ———. Pandora’s Lab: Seven Stories of Science Gone Wrong. Washington, DC: National Geographic Society, 2017.
  87. ———. Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases. Washington, DC: Smithsonian Books, 2008.
  88. Oppenheimer, Jerry. Crazy Rich: Power, Scandal, and Tragedy Inside the Johnson & Johnson Dynasty. New York: St. Martin’s, 2014.
  89. Oshinsky, David M. Polio: An American Story. Oxford, UK: Oxford University Press, 2006.
  90. Pekkanen, John. The American Connection; Profiteering and Politicking in the “Ethical” Drug Industry. Chicago: Follett Pub. Co., 1973.
  91. Pepin, Jacques. The Origin of AIDS. Cambridge, UK: Cambridge University Press, 2012.
  92. Petersen, Melody. Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs. New York: Picador, 2009.
  93. Podolsky, M. Lawrence. Cures Out of Chaos: How Unexpected Discoveries Led to Breakthroughs in Medicine and Health. Amsterdam: Harwood Academic Publishers, 1997.
  94. Podolsky, Scott H. The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics. Baltimore, MD: Johns Hopkins University Press, 2015.
  95. Portenoy, Russell K., and Ronald M. Kanner. Pain Management: Theory and Practice. Philadelphia, PA: F. A. Davis Comp., 1996.
  96. Pringle, Peter. Experiment Eleven: Dark Secrets behind the Discovery of a Wonder Drug. New York: Bloomsbury, 2013.
  97. Quammen, David. The Chimp and the River: How AIDS Emerged from an African Forest. New York: W. W. Norton & Company, 2015.
  98. Quick, Jonathan D., and Bronwyn Fryer. The End of Epidemics: The Looming Threat to Humanity and How to Stop It. New York: St. Martin’s Press, 2018.
  99. Quinones, Sam. Dreamland: The True Tale of America’s Opiate Epidemic. London: Bloomsbury Press, 2015.
  100. Rasmussen, Nicolas. On Speed: The Many Lives of Amphetamine. New York: New York University Press, 2009.
  101. Redwood, Heinz. Pharmapolitics 2000: Key Issues for the Industry. Richmond, Surrey, UK: Oldwicks Press, 1997.
  102. Rodengen, Jeffrey L. The Legend of Pfizer. Fort Lauderdale, FL: Write Stuff Syndicate, 1999.
  103. Rosen, William. Miracle Cure: The Creation of Antibiotics and the Birth of Modern Medicine. New York: Viking, 2017.
  104. Rosenbaum, Lee. The Complete Guide to Collecting Art. New York: Alfred A. Knopf, 1982.
  105. Rost, Peter. The Whistleblower: Confessions of a Healthcare Hitman. Brooklyn, NY: Soft Skull Press, 2006.
  106. Rothstein, William G. American Physicians in the Nineteenth Century: From Sects to Science. Baltimore, MD: Johns Hopkins University Press, 1992.
  107. Sackler, Arthur M., Mortimer D. Sackler, Raymond R. Sackler, Felix Marti-Ibanez, and Ugo Cerletti, eds., The Great Physiodynamic Therapies in Psychiatry: An Historical Reappraisal. New York: Hoeber-Harper Medical, 1956.
  108. Salzman, Carl. Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report. Washington, DC: American Psychiatric Association, 1990.
  109. Schur, Edwin M. Labeling Women Deviant: Gender, Stigma, and Social Control. New York: McGraw-Hill, 1984.
  110. Schwarcz, Vera. Place and Memory in the Singing Crane Garden. Philadelphia, PA: University of Pennsylvania Press, 2014.
  111. Schwartzman, David. Innovation in the Pharmaceutical Industry. Baltimore, MD: Johns Hopkins University Press, 1976.
  112. Schwarz, Alan. ADHD Nation: Children, Doctors, Big Pharma, and the Making of an American Epidemic. New York: Little, Brown and Company, 2017.
  113. Seaman, Barbara. The Doctor’s Case against the Pill. Alameda, CA: Hunter House, 2000.
  114. ———. The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth. New York: Seven Stories, 2009.
  115. Shilts, Randy. And the Band Played On: Politics, People, and the AIDS Epidemic, 20th Anniversary Edition. New York: St. Martin’s Griffin, 2007, Kindle Edition, 2007.
  116. Shook, Robert L. Miracle Medicines: Seven Lifesaving Drugs and the People Who Created Them. New York: Portfolio, 2014.
  117. Shorter, Edward. Before Prozac: The Troubled History of Mood Disorders in Psychiatry. Oxford, UK: Oxford University Press, 2009.
  118. Shryock, Richard. American Medical Research Past and Present. New York: Commonwealth Fund, 1947.
  119. ———. The Development of Modern Medicine: An Interpretation of the Social and Scientific Factors Involved. New York: Alfred A. Knopf, 1936.
  120. Silverman, Milton, and Philip R. Lee. Pills, Profits and Politics. Berkeley, CA: University of California Press, 1974.
  121. Smith, Mickey C. Pharmaceutical Marketing: Strategy and Cases. New York: Informa Healthcare, 2009.
  122. ———. Principles of Pharmaceutical Marketing. Philadelphia, PA: Lea & Febiger, 1983.
  123. ———. A Social History of the Minor Tranquilizers: The Quest for Small Comfort in the Age of Anxiety. London: Pharmaceutical Press, 1991.
  124. Spink, Wesley W. Infectious Diseases: Prevention and Treatment in the Nineteenth and Twentieth Centuries. Minneapolis, MN: University of Minnesota Press, 1978.
  125. Starr, Douglas P. Blood: An Epic History of Medicine and Commerce. New York: Harper Perennial, 2002.
  126. Starr, Paul. The Social Transformation of American Medicine: The Rise of a Sovereign Profession and the Making of a Vast Industry. New York: Basic Books, 2017.
  127. Stelzer, Irwin M. Selected Antitrust Cases: Landmark Decisions. Homewood, IL: Richard Irwin, 1981.
  128. Stoller, K. Paul. Incurable Me: Why the Best Medical Research Does Not Make It into Clinical Practice. New York: Skyhorse Publishing, 2016.
  129. Sullivan, Mark. Our Times: The United States 1900–1925. Vol. 2 of America Finding Herself. New York: Charles Scribner’s Sons, 1927.
  130. Tanner, Adam. Our Bodies, Our Data: How Companies Make Billions Selling Our Medical Records. Boston: Beacon Press, 2017.
  131. Tanner, Ogden. 25 Years of Innovation: The Story of Pfizer Central Research. Lyme, CT: Greenwich Publishing Group, 1996.
  132. Temin, Peter. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press, 1980.
  133. Tobbell, Dominique A. Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and Its Consequences. Berkeley, CA: University of California Press, 2012.
  134. Tone, Andrea. The Age of Anxiety: A History of America’s Turbulent Affair with Tranquilizers. New York: Basic Books, 2012.
  135. Tone, Andrea, and Elizabeth Siegel Watkins. Medicating Modern America: Prescription Drugs in History. New York: New York University Press, 2007.
  136. Vagelos, Roy, and Louis Galambos. Medicine, Science, and Merck. New Cambridge, UK: Cambridge University Press, 2004.
  137. Vagelos, Roy, Louis Galambos, and Pindaros Roy. The Moral Corporation: Merck Experiences. Cambridge, UK: Cambridge University Press, 2006.
  138. Verg, Erik, Gottfried Plumpe, and Heinz Schultheis. Milestones: The Bayer Story, 1863–1988. Leverkusen, Germany: Bayer AG, 1988.
  139. Villafana, Frank. Coercion as Cure: A Critical History of Psychiatry. Abingdon-on-Thames, UK: Routledge, 2017.
  140. Wald, Alan M. American Night: The Literary Left in the Era of the Cold War. Chapel Hill, NC: University of North Carolina Press, 2014.
  141. Weinberg, Eric, and Donna Shaw. Blood on Their Hands: How Greedy Companies, Inept Bureaucracy, and Bad Science Killed Thousands of Hemophiliacs. New Brunswick, NJ: Rutgers University Press, 2017.
  142. Welch, Henry, and Félix Martí-Ibáñez. The Antibiotic Saga. New York: Medical Encyclopedia, 1960.
  143. Whitaker, Robert. Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. New York: Crown, 2010.
  144. Wiley, Harvey W. An Autobiography. Indianapolis, IN: The Bobbs-Merrill Company, 1930.
  145. ———. The History of a Crime against the Food Law. Washington, DC: Harvey W. Wiley, 1929.
  146. Wolpe, Joseph. Orientation to Behavior Therapy. Nutley, NJ: Hoffmann-La Roche, 1971.
  147. Young, James Harvey. The Medical Messiahs: A Social History of Health Quackery in Twentieth-Century America. Princeton, NJ: Princeton University Press, 1967.
  148. ———. Pure Food: Securing the Federal Food and Drugs Act of 1906. Princeton, NJ: Princeton University Press, 1989.
  149. ———. The Toadstool Millionaires: A Social History of Patent Medicines in America before Federal Regulation. Princeton, NJ: Princeton University Press, 1961.

Articles, Reports, and Other Publications

  1. Achenbach, Joel. “Once ‘So Mayberry,’ a Town Struggles with Opioid Epidemic.” The Washington Post, December 30, 2016.
  2. Adams, Rebecca, and Kate Shuler. “Lawmakers Weigh Incentives for High-Risk Vaccine Business.” Congressional Quarterly Weekly Report 61, no. 41 (October 30, 2004).
  3. Adams, Samuel Hopkins. “The Great American Fraud.” “The Nostrum Evil.” October 7, 1905; “Peruna and the Bracers.” October 28, 1905; “Liquozone.” November 18, 1905; “The Subtle Poisons.” December 2, 1905; “A Fraud’s Gallery.” January 13, 1906; “The Fundamental Fakes.” February 17, 1906. Collier’s.
  4. Alleyne, Richard. “Widespread Antibiotic Use in 1960s Sparked MRSA.” The Telegraph, January 22, 2010.
  5. Altman, Lawrence K. “In Philadelphia 30 Years Ago, an Eruption of Illness and Fear.” The New York Times, August 1, 2006.
  6. Amaral-Zettler, L., L. F. Artigas, J. Baross, L. Bharathi, A. Boetius, D. Chandramohan, G. Herndl, K. Kogure, P. Neal, C. Pedros-Alio, A. Ramette, S. Schouten, L. Stal, A. Thessen, J. de Leeuw, and M. Sogin. “A Global Census of Marine Microbes.” In Life in the World’s Oceans: Diversity, Distribution and Abundance, edited by Alasdair D. McIntyre. Oxford, UK: Blackwell Publishing Ltd, 2010.
  7. Angst, J. “Panic Disorder: History and Epidemiology.” Eur Psychiatry 13, no. S2 (1998): S51–55.
  8. “Antibiotics at Risk.” Editorial, The British Medical Journal 2, no. 5971 (1975): 582.
  9. Armstrong, Terry. “Distribution in Jig Time: The Story of Terramycin.” Sales Management 66 (1951).
  10. “ASPMN Backs Pain Champion: Russell Portenoy.” Pain Management Nursing 14, no. 1 (January 22, 2013).
  11. Austin, T. “Mixed Drug Overdosage with Phenelzine, Amytal and Chlordiazepoxide. A Case Report.” Anaesthesia 21, no. 2 (1966): 249–52.
  12. Bachhuber, M. A., S. Hennessy, C. O. Cunningham, and J. L. Starrels. “Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013.” American Journal of Public Health 106, no. 4 (2016): 686–88.
  13. Balch, Robert J., and Andrea Trescot. “Extended-Release Morphine Sulfate in Treatment of Severe Acute and Chronic Pain.” Journal of Pain Research 3 (September 21, 2010): 191–200.
  14. Barber, Mary. “Staphylococcal Infection Due to Penicillin-Resistant Strains.” The British Medical Journal 2 (1947).
  15. Barber, Mary, and Mary Rozwadowska-Dowzenko. “Infection by Penicillin-Resistant Staphylococci.” The Lancet 255 (1948).
  16. Bassett, M. T., and M. Mhloyi. “Women and AIDS in Zimbabwe: The Making of an Epidemic.” International Journal of Health Services 1, no. 21 (1991): 143–56.
  17. Bax, Richard P. “Antibiotic Resistance: A View from the Pharmaceutical Industry.” Clinical Infectious Diseases 24 (1997).
  18. Bedard, Nicholas A., Andrew J. Pugely, et al. “Opioid Use after Total Knee Arthroplasty: Trends and Risk Factors for Prolonged Use.” The Journal of Arthroplasty 32, no. 8 (August 2017).
  19. Belongia, Edward A., and Allison L. Naleway. “Smallpox Vaccine: The Good, the Bad, and the Ugly.” Clinical Medicine and Research 1, no. 2 (2003).
  20. Bennet, Amanda, and Anita Sharpe. “Federal AIDS Campaign Neglects High-Risk Groups.” The Wall Street Journal, May 1, 1996.
  21. Berndt, Ernst R., and Murray Aitken. “Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation.” International Journal of the Economics of Business 18, no. 2 (July 2011).
  22. Bero, L., F. Oostvogel, P. Bacchetti, and K. Lee. “Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others.” PLOS Medicine 6, no. 4 (June 5, 2007): e184.
  23. Boehma, Garth, et al. “Development of the Generic Drug Industry in the US after the Hatch-Waxman Act of 1984.” Acta Pharmaceutica Sinica B 3, no. 5 (September 2013).
  24. Boffey, Philip M. “Worldwide Use of Valium Draws New Scrutiny.” The New York Times, October 13, 1981.
  25. Bogdan, Herman A. “Félix Martí-Ibáñez—Iberian Daedalus: The Man behind the Essays.” Journal of the Royal Society of Medicine 86 (October 1993): 593–96.
  26. Borger, Julian. “Hillbilly Heroin: The Painkiller Abuse Wrecking Lives in West Virginia.” The Guardian (UK), June 24, 2001.
  27. Brady, Joseph V. “Ulcers in ‘Executive’ Monkeys.” Scientific American, October 1958.
  28. Brody, Jane E. “Birth Control Pills: A Balance Sheet on Their National Impact.” The New York Times, March 23, 1969.
  29. Bryan, Jenny. “From Snake Venom to ACE Inhibitor—the Discovery and Rise of Captopril.” The Pharmaceutical Journal (April 17, 2009).
  30. Bud, Robert. “Antibiotics, Big Business, and Consumers: The Context of Government Investigations into the Postwar American Drug Industry.” Technology and Culture 46, no. 2 (2005): 329–49.
  31. ———. “Resisting Antibiotics: The Social Challenges of Drug Reform.” Boston Review, October 27, 2015.
  32. ———. “Upheaval in the Moral Economy of Science? Patenting, Teamwork and the World War II Experience of Penicillin.” History and Technology 24, no. 2 (2008).
  33. Burrows, Adam. “Palette of Our Palates: A Brief History of Food and Its Regulation.” Comprehensive Reviews in Food Science and Food Safety 8 (2009).
  34. Bush, Karen. “The Coming of Age of Antibiotics: Discovery and Therapeutic Value.” Antimicrobial Therapeutics Reviews (December 23, 2010).
  35. Cacciapaglia, Frank, and Howard B. Rockman. “The Proposed Drug Industry Antitrust Act: Patents, Pricing, and the Public.” George Washington Law Review 30, no. 5 (June 1962).
  36. Calcaterra, Nicholas E., and James C. Barrow. “Classics in Chemical Neuroscience: Diazepam (Valium).” ACS Chemical Neuroscience 5, no. 4 (2014).
  37. Cant, Gilbert B. “Valiumania.” The New York Times Magazine, February 1, 1976.
  38. Castagnoli, William G. “There Were Giants in Those Days.” Medical Marketing & Media, March 1, 1997.
  39. ———. “Remembrance of Kings Past.” Medical Marketing & Media 31, no. 7 (July 1, 1996): 44.
  40. Castro, K. G., A. R. Lifson, C. R. White, et al. “Investigations of AIDS Patients with No Previously Identified Risk Factors.” JAMA 259, no. 9 (1988).
  41. Catan, Thomas, and Evan Perez. “A Pain-Drug Champion Has Second Thoughts.” The Wall Street Journal, December 17, 2012.
  42. Cavers, David F. “The Food, Drug, and Cosmetic Act of 1938: Its Legislative History and Its Substantive Provisions.” Law and Contemporary Problems 6 (Winter 1939), 2–42.
  43. Chelminski, P. R., et al. “A Primary Care, Multi-Disciplinary Disease Management Program for Opioid-Treated Patients with Chronic Non-Cancer Pain and a High Burden of Psychiatric Comorbidity.” BMC Health Services Research 5, no. 1 (2005): 3.
  44. Cicero, T., J. Inciardi, and A. Munoz. “Trends in Abuse of OxyContin and Other Opioid Analgesics in the United States: 2002–2004.” The Journal of Pain 6 (2005): 662–72.
  45. Clines, Francis X., and Barry Meier. “Cancer Painkillers Pose New Abuse Threat.” The New York Times, February 9, 2001.
  46. Cobb, W. Montague. “Louis Tompkins Wright, 1891–1952.” JAMA 45 (March 1953).
  47. Cohen, David. “The Opioid Timebomb: The Sackler Family and How Their Painkiller Fortune Helps Bankroll London Arts.” The Evening Standard, March 19, 2018.
  48. ———“The Sackler Files” (Multi-part investigation into tax avoidance). The Evening Standard, May 11, 2018. See the entire series at http://www.standard.co.uk/opioids.
  49. Cohen, Jon. “Searching for the Epidemic’s Origins.” Science 288, no. 5474 (June 23, 2000).
  50. Cohen, Kelly, R. L. Semple, P. Bialer, A. Lau, A. Bodenheimer, and I. Galynker. “Relationship between Drug Company Funding and Outcomes of Clinical Psychiatric Research.” Psychological Medicine 36, no. 11 (2006): 1647–56.
  51. Cohen, Pieter A., Alberto Goday, and John P. Swann. “The Return of Rainbow Diet Pills.” American Journal of Public Health 102, no. 9 (2012).
  52. Comfort, Nathaniel. “The Prisoner as Model Organism: Malaria Research at Stateville Penitentiary.” Studies in History and Philosophy of Biological and Biomedical Sciences 40, no. 3 (2009).
  53. Cooper, Arnie. “An Anxious History of Valium.” The Wall Street Journal, November 15, 2013.
  54. Cooperstock, Ruth. “Sex Differences in the Use of Mood-Modifying Drugs: An Explanatory Model.” Journal of Health and Social Behavior 12, no. 3 (1971).
  55. Costello, Peter M. “The Tetracycline Conspiracy: Structure, Conduct and Performance in the Drug Industry.” Antitrust Law & Economic Review 1 (1968): 13–44.
  56. Cramp, Arthur J. “Nostrums and Quackery: Collected Articles on the Nostrum Evil and Quackery.” Reprint by JAMA. Chicago: American Medical Association Press, January 1, 1912.
  57. Crane, George E. “Advances in the Drug Therapy of Mental Illness.” American Journal of Psychiatry 134, no. 6 (June 1977).
  58. Davis, Michael Henry, Peter S. Arno, and Karen Bonuck. “Rare Diseases, Drug Development and AIDS: The Impact of the Orphan Drug Act.” Milbank Quarterly 73, no. 231 (1995).
  59. Dehner, G. “WHO Knows Best?: National and International Responses to Pandemic Threats and the ‘Lessons’ of 1976.” Journal of the History of Medicine and Allied Sciences 65, no. 4 (2010).
  60. Delaney, Martin. “Double Jeopardy for Gallo.” Science 296, no. 5573 (May 31, 2002).
  61. Deschamps, J. R. “The Role of Crystallography in Drug Design.” The AAPS Journal 7, no. 4 (2005): E813–19.
  62. De Sousa, João Dinis, et al. “Enhanced Heterosexual Transmission Hypothesis for the Origin of Pandemic HIV-1.” Viruses 4, no. 10 (2012): 1950–83.
  63. Di Justo, Patrick. “The Last Great Swine Flu Epidemic.” Salon, April 28, 2009.
  64. DiMasi, Joseph A., and Cherie Paquette. “The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development.” PharmacoEconomics 2, no. S2 (2004).
  65. Doern, G. V., M. J. Ferraro, A. B. Brueggemann, and K. L. Ruoff. “Emergence of High Rates of Antimicrobial Resistance Among Viridans Group Streptococci in the United States.” Antimicrobial Agents and Chemotherapy 40 (1996): 891–94.
  66. Donohue, Julie. “A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection.” The Milbank Quarterly 84, no. 4 (2006): 659–99.
  67. Drews, Gustav. “Federal Drug Regulation Act.” Brooklyn Law Review 29, no. 1 (December 1962): 91–97.
  68. Drucker, E., P. G. Alcabes, and P. A. Marx. “The Injection Century: Massive Unsterile Injections and the Emergence of Human Pathogens.” The Lancet 358, no. 9297 (December 8; 2001): 1989–92.
  69. Duggar, Benjamin M. “Aureomycin: A Product of the Continuing Search for New Antibiotics.” Annals of the New York Academy of Sciences 51 (1948).
  70. Dunklin, A. “The Reality of Prescribing Opioids in Texas: An Interview with a Drug Agent.” Interview by Anita L. Comley. Baylor University Medical Center Proceedings 13, no. 3 (2000).
  71. Eccles, R. G. “Radam’s Microbe Killer.” Druggists Circular and Chemical Gazette 33 (1889).
  72. Edlund, Mark J., Mark Sullivan, Diane Steffick, Katherine M. Harris, and Kenneth B. Wells. “Do Users of Regularly Prescribed Opioids Have Higher Rates of Substance Use Problems Than Nonusers?” Pain Medicine 8, no. 8 (November 1, 2007).
  73. Eggertson, Laura. “Lancet Retracts 12-Year-Old Article Linking Autism to MMR Vaccines.” Canadian Medical Association Journal 182, no. 4 (2010): E199–200.
  74. Ehrenkranz, N., et al. “Pneumocystis Carinii Pneumonia among Persons with Hemophilia A.” Morbidity and Mortality Weekly Report (1982).
  75. Elliott, Carl. “The Drug Pushers.” The Atlantic, April 2006.
  76. Epstein, Richard Seth. “The Isolation and Purification Exception to the General Unpatentability of Products of Nature.” Columbia Science and Technology Review, January 15, 2003.
  77. Esbjörnsson, Joakim, et al. “HIV-1 Molecular Epidemiology in Guinea-Bissau, West Africa: Origin, Demography and Migrations.” Edited by Sheila Bowyer. PLOS One 6, no. 2 (2011): e17025.
  78. Facchinetti, N. J., and W. M. Dickson. “Access to Generic Drugs in the 1950s: The Politics of a Social Problem.” American Journal of Public Health 72, no. 5 (1982).
  79. Fair, Richard J., and Yitzhak Tor. “Antibiotics and Bacterial Resistance in the 21st Century.” Perspectives in Medicinal Chemistry 6 (2014): 25–64.
  80. “The Federal Trade Commission Act of 1938.” Columbia Law Review 39, no. 2 (1939): 259–73.
  81. Feldman, Robin, Evan Frondorf, Andrew Cordova, and Connie Wang. “Empirical Evidence of Drug Pricing Games—A Citizen’s Pathway Gone Astray.” Stanford Technology Law Review 20, no. 1 (2017).
  82. Ferner, Robin. “A Short History of Pharmaceutical Marketing.” The BMJ 345, no. 7884 (2012).
  83. Fineberg, Harvey V. “Swine Flu of 1976: Lessons from the Past.” Bulletin of the World Health Organization 87, no. 6 (June 2009).
  84. Fishbain, David A., Brandly Cole, John Lewis, Hubert L. Rosomoff, and R. Steele Rosomoff. “What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review.” Pain Medicine 9, no. 4 (May 1, 2008).
  85. Fitzpatrick, Michael. “The Cutter Incident: How America’s First Polio Vaccine Led to a Growing Vaccine Crisis.” Journal of the Royal Society of Medicine 99, no. 3 (2006).
  86. Fleming, M. F., J. Davis, and S. D. Passik. “Reported Lifetime Aberrant Drug-Taking Behaviors Are Predictive of Current Substance Use and Mental Health Problems in Primary Care Patients.” Pain Medicine 9, no. 8 (2008).
  87. Fletcher, Charles. “First Clinical Use of Penicillin.” The BMJ 289 (1984).
  88. Foley, K. M., J. J. Fins, and C. E. Inturrisi. “A True Believer’s Flawed Analysis.” Archives of Internal Medicine 171, no. 9 (2011).
  89. Frohlich, L. W. “The Physician in the Pharmaceutical Industry in the United States.” Proceedings of the Royal Society of Medicine from April 11, 1960, London. 53, sec. 1 (August 1960): 579–86.
  90. Fugh-Berman, Adriane, and Shahram Ahari. “Following the Script: How Drug Reps Make Friends and Influence Doctors.” PLOS Medicine 4, no. 4 (2007).
  91. Fullerton, W. S. “The Objectionable Influence of Proprietary Medicines Upon the Young Practitioner.” Journal of the Minnesota State Medical Association and the Northwestern Lancet 26 (October 15, 1906).
  92. Galambos, L., and J. L. Sturchio. “Transnational Investment: The Merck Experience, 1891–1925.” In Hans Pohl, ed., Transnational Investment from the 19th Century to the Present. Stuttgart, Germany: Franz Steiner Verlag, 1994.
  93. Gardner, M. N., and A. M. Brandt. “The Doctors’ Choice Is America’s Choice: The Physician in US Cigarette Advertisements, 1930–1953.” American Journal of Public Health 96, no. 2 (2006).
  94. Gaughan, Anthony. “Harvey Wiley, Theodore Roosevelt, and the Federal Regulation of Food and Drugs.” Third-Year Paper at Harvard Law School (Winter 2004).
  95. Gaul, Gilbert M. “How Blood, the ‘Gift of Life,’ Became a Billion-Dollar Business.” The Philadelphia Inquirer, March 12, 1989.
  96. Gaydos, J., R. Hodder, et al. “Swine Influenza A at Fort Dix, New Jersey (January–February 1976), II. Transmission and Morbidity in Units with Cases.” The Journal of Infectious Diseases (December 13, 1977): S363–68.
  97. Glacek, Christopher. “The Secretive Family Making Billions from the Opioid Crisis.” Esquire, October 16, 2017.
  98. Glueck, Grace. “An Art Collector Sows Largesse and Controversy.” The New York Times, June 5, 1983.
  99. ———. “Dr. Arthur Sackler Dies at 73; Philanthropist and Art Patron.” The New York Times, May 27, 1987.
  100. ———. “Sackler Art Museum To Open At Harvard.” The New York Times, October 18, 1985.
  101. Godlee, F. “The Fraud Behind the MMR Scare.” The BMJ 342 (2011): 22.
  102. Gong, Z., X. Xu, and G. Z. Han. “Patient ‘0’ and the Origin of HIV/AIDS in America.” Trends in Microbiology 25, no. 1 (January 2017): 3–4.
  103. Gormus, B. J., L. N. Martin, and G. B. Baskin. “A Brief History of the Discovery of Natural Simian Immunodeficiency Virus (SIV) Infections in Captive Sooty Mangabey Monkeys.” Frontiers in Bioscience 9 (January 1, 2004): 216–24.
  104. Gottlieb, M. S., R. Schroff, H. M. Schanker, J. D. Weisman, P. T. Fan, R. A. Wolf, and A. Saxon. “Pneumocystis Carinii Pneumonia and Mucosal Candidiasis in Previously Healthy Homosexual Men: Evidence of a New Acquired Cellular Immunodeficiency.” The New England Journal of Medicine 305, no. 24 (December 10, 1981): 1425–31.
  105. Gøtzsche, Peter C. “Big Pharma Often Commits Corporate Crime, and This Must Be Stopped.” The BMJ 346, no. 7894 (2013): 26.
  106. Grabowski, Henry. “The Evolution of the Pharmaceutical Industry over the Past 50 Years: A Personal Reflection.” International Journal of the Economics of Business 18, no. 2 (July 2011).
  107. Greene, J. A., and D. Herzberg. “Hidden in Plain Sight: Marketing Prescription Drugs to Consumers in the Twentieth Century.” American Journal of Public Health 100, no. 5 (2010): 793–803.
  108. Greene, Marion S., and R. Andrew Chambers. “Pseudoaddiction: Fact or Fiction? An Investigation of the Medical Literature.” Current Addiction Reports 2, no. 4 (2015): 310–17.
  109. Gürtler, Leon. “Merck in America: The First 70 Years from Fine Chemicals to Pharmaceutical Giant.” Bulletin for the History of Chemistry 25, no. 1 (2000).
  110. Gürtler, Leon, and J. Eberle. “Aspects on the History of Transmission and Favor of Distribution of Viruses by Iatrogenic Action: Perhaps an Example of a Paradigm of the Worldwide Spread of HIV.” Medical Microbiology Immunology 206, no. 4 (August 2017): 287–93.
  111. Hadland, S. E., M. Cerdá, Y. Li, M. S. Krieger, and B. D. L. Marshall. “Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians with Subsequent Opioid Prescribing.” JAMA Internal Medicine 178, no. 6 (2018): 861–63.
  112. Hahn, Beatrice H., et al. “AIDS as a Zoonosis: Scientific and Public Health Implications.” Science 287, no. 5453 (January 28, 2000).
  113. Hall, Wendell H. “The Abuse and Misuse of Antibiotics.” Minnesota Medicine 35 (1952).
  114. Haller, John S., Jr. “Antibiotic Era.” Pharmacy in History 56, nos. 1–2 (2014).
  115. Hamowy, Ronald. “The Early Development of Medical Licensing Laws in the United States, 1875–1900.” The Journal of Libertarian Studies 3 (1979).
  116. Harding, Herbert. “The History of the Organization among Manufacturers and Wholesale Dealers in Proprietary Articles.” American Druggist 36 (1900).
  117. Harris, Gardiner. “How Merck Survived while Others Merged—Drug Maker Relied on Inspired Research.” The New York Times, January 12, 2001.
  118. Hart, F. Leslie. “A History of the Adulteration of Food Before 1906.” Food, Drug, Cosmetic Law Journal 7 (1952).
  119. Heit, H. A. “Addiction, Physical Dependence, and Tolerance.” Journal of Pain & Palliative Care Pharmacotherapy 17, no. 1 (2003).
  120. Helm, Katherine A. “Protecting Public Health from Outside the Physician’s Office: A Century of FDA Regulation from Drug Safety Labeling to Off-Label Drug Promotion.” Fordham Intellectual Property, Media and Entertainment Law Journal 18, no. 1 (2007): article 9.
  121. Herper, Matthew. “The Best-Selling Drugs in America.” Forbes, April 19, 2011.
  122. ———. “A Biotech Phoenix Could Be Rising.” Forbes, September 25, 2002.
  123. ———. “Solving the Drug Patent Problem.” Forbes, May 2, 2002.
  124. Herxheimer, Andrew, Cecilia Stålsby Lundborg, and Barbro Westerholm. “Advertisements for Medicines in Leading Medical Journals in 18 Countries: A 12-Month Survey of Information Content and Standards.” International Journal of Health Services 23, no. 1 (January 1993).
  125. Hicks, Jesse. “Fast Times: The Life, Death, and Rebirth of Amphetamine.” Distillations, Science History Institute, April 14, 2014.
  126. Higano, R., W. N. Robinson, and W. D. Cohen. “Effects of Long-Term Administration of Estrogens on Serum Lipids of Postmenopausal Women.” The New England Journal of Medicine 263: 828–31.
  127. “History of Federal Regulation: 1902–Present: Food, Drug, and Cosmetic Act of 1938.” FDAReview.org, A Project of the Independent Institute. http://www.fdareview.org/01_history.php.
  128. Ho, J. M., and D. N. Juurlink. “Considerations When Prescribing Trimethoprim-Sulfamethoxazole.” Canadian Medical Association Journal 183, no. 16 (2011): 1851–58.
  129. Hollister, Leo E., Francis P. Motzenbecker, and Roger O. Degan. “Withdrawal Reactions from Chlordiazepoxyd (Librium).” Psychopharmacology 2, no. 1 (January 1961): 63–68.
  130. Hønge, Bo Langhoff, et al. “High Prevalence and Excess Mortality of Late Presenters among HIV-1, HIV-2 and HIV-1/2 Dually Infected Patients in Guinea-Bissau—A Cohort Study from West Africa.” The Pan African Medical Journal 25 (2016): 40.
  131. Hooper, Edward, et al. “Search for the Origin of HIV and AIDS.” Science 289, no. 5482 (August 18, 2000).
  132. Horowitz, Nathan. “Arthur M. Sackler, MD.” Medical Tribune 25, no. 22 (June 10, 1987).
  133. Houck, J. A. “ ‘What Do These Women Want?’: Feminist Responses to Feminine Forever.” Bulletin of the History of Medicine 77, no. 1 (Spring 2003).
  134. Howell, Mary C. “What Medical Schools Teach About Women.” The New England Journal of Medicine 291 (August 8, 1974).
  135. Inciardi, James, and Jennifer Goode. “OxyContin and Prescription Drug Abuse.” Consumer’s Research (July 2003).
  136. Isis, Doogab Yi. “Who Owns What? Private Ownership and the Public Interest in Recombinant DNA Technology in the 1970s.” The University of Chicago Press on behalf of the History of Science Society 102, no. 3 (September 2011).
  137. Jacobs, Andrew. “Citrus Farmers Facing Deadly Bacteria Turn to Antibiotics, Alarming Health Officials.” The New York Times, May 17, 2019.
  138. Jawetz, Ernest. “Infectious Diseases: Problems of Antimicrobial Therapy.” Annual Review of Medicine 5 (1954).
  139. Jayawant, Sujata S., and Rajesh Balkrishnan. “The Controversy Surrounding Oxycontin Abuse: Issues and Solutions.” Therapeutics and Clinical Risk Management 1, no. 2 (2005).
  140. Jones, C. M., E. B. Einstein, and W. M. Compton. “Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010–2016.” JAMA 319, no. 17 (2018): 1819–21.
  141. Joseph, Andrew. “Purdue Cemented Ties with Universities and Hospitals to Expand Opioid Sales, Documents Contend.” STAT News, January 16, 2019.
  142. Jurtshuk, Peter, Jr., et al. “Biochemical Responses of Rats to Auditory Stress.” Science, May 22, 1959.
  143. Kaiko, Robert F., et al. “The United States Experience with Oral Controlled-Release Morphine (MS Contin Tablets), Parts I and II. Review of Nine Dose Titration Studies and Clinical Pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg Tablet Strengths in Normal Subjects.” Cancer 63 (June 1, 1989): 2348–54. Note: team of writers from the Medical Department of the Purdue Frederick Company, Norwalk, CT, and Yonkers, New York.
  144. Karki, L. “Review of FDA Law Related to Pharmaceuticals: The Hatch-Waxman Act, Regulatory Amendments and Implications for Drug Patent Enforcement.” Journal of the Patent Trademark and Office Society 87 (2005).
  145. Keefe, Patrick Radden. “The Family that Built an Empire of Pain.” The New Yorker, October 23, 2017.
  146. Kent, Francis B. “Rising Criticism—Haiti: Jobless, Poor Line Up to Sell Blood.” Los Angeles Times, January 27, 1972.
  147. Khazan, Olga. “The New Heroin Epidemic.” The Atlantic, October 30, 2014.
  148. Kiang, M. V., S. Basu, J. Chen, and M. J. Alexander. “Assessment of Changes in the Geographical Distribution of Opioid-Related Mortality across the United States by Opioid Type, 1999–2016.” JAMA Network Open (2019).
  149. Kingston, William. “Streptomycin, Schatz v. Waksman, and the Balance of Credit for Discovery.” Journal of the History of Medicine and Allied Sciences 59 (2004).
  150. Kirby, T. J. “Cataracts Produced by Triparanol. (MER-29).” Transactions of the American Ophthalmological Society 65 (1967): 494–543.
  151. Kitt, G. W. “Benjamin Minge Duggar: 1872–1956.” Mycologia 39, no. 3 (May–June 1957).
  152. Korber, B., et al. “Timing the Ancestor of the HIV-1 Pandemic Strains.” Science 288, no. 5472 (June 9, 2000).
  153. Kornbluth, Jesse. “The Temple of Sackler.” Vanity Fair, September 1987.
  154. Krause, Richard. “The Swine Flu Episode and the Fog of Epidemics.” Emerging Infectious Diseases 12, no. 1 (January 2006).
  155. Kreston, Rebecca. “The Public Health Legacy of the 1976 Swine Flu Outbreak.” Discover, September 30, 2013.
  156. Krupka, L. R., and A. M. Vener. “Gender Differences in Drug (Prescription, Non-Prescription, Alcohol and Tobacco) Advertising: Trends and Implications.” Journal of Drug Issues 22, no. 2 (April 1992).
  157. Lall, Sanjaya. “Multinational Companies and Concentration: The Case of the Pharmaceutical Industry.” Social Scientist 7, no. 8/9 (1979).
  158. Larkin, Timothy. “The New Flu: What It Is and What Is Being Done About It.” FDA Consumer 10, no. 4 (May 1976).
  159. Laven, Stuart A. “Invalid Patents: Removing Statutory Protection from Improperly Granted Monopolies.” Case Western Reserve Law Review 21, no. 2 (1970).
  160. Lear, John. “The Certification of Antibiotics.” Saturday Review (February 7, 1959): 43–48.
  161. ———. “Do We Need a Census of Worthless Drugs?” Saturday Review (May 7, 1960).
  162. ———. “Taking the Miracle Out of the Miracle Drugs.” Saturday Review 42 (January 3, 1959).
  163. Lenzner, Robert. “A Financial Man and the Fogg.” The Boston Globe, February 16, 1982.
  164. Leung, Pamela T. M., Erin M. Macdonald, Matthew B. Stanbrook, Irfan A. Dhalla, Li Ka Shing, and David N. Juurlink. “A 1980 Letter on the Risk of Opioid Addiction.” The New England Journal of Medicine 376 (June 1, 2017): 2194–95.
  165. Levin, Tamar. “Drug Makers Fighting Back Against Advance of Generics.” The New York Times, July 28, 1987.
  166. Liebeskind, J. C. “Pain Can Kill.” Pain 44, no. 1 (January 1991).
  167. Lombardino, Joseph G. “A Brief History of Pfizer Central Research.” Bulletin for the History of Chemistry 25, no. 1 (2000).
  168. López-Muñoz, Francisco, Ronaldo Ucha-Udabe, and Cecilio Alamo. “The History of Barbiturates a Century after Their Clinical Introduction.” Neuropsychiatric Disease and Treatment 1, no. 4 (2005): 329–43.
  169. Mandell, D. T., et al. “Pathogenic Features Associated with Increased Virulence upon Simian Immunodeficiency Virus Cross-Species Transmission from Natural Hosts.” Journal of Virology 88, no. 12 (June 2014): 6778–92.
  170. Mangano, Michael F. “A Multi-Disciplinary Approach to Problem Solving: The Generic Drug Scandal.” The Government Accountants Journal (Fall 1992).
  171. Mant, A., and D. Darroch. “Media Images and Medical Images.” Social Science & Medicine (1975).
  172. Martí-Ibáñez, Félix. “The Artist as Physician; Medical Philosophy in the Renaissance.” International Record of Medicine and General Practice Clinics 167, no. 4 (April 1954): 221–42.
  173. ———. “Doctors Must Tell.” International Record of Medicine and General Practice Clinics 172 (October 1959): 651–52.
  174. ———. “The Epic of Medicine, IV. A Torrent of Lions (Medicine in Imperial Rome) 285 BC–AD 476.” International Record of Medicine and General Practice Clinics 172 (November 1959): 719–22.
  175. ———. “The Epic of Medicine, V. Through a Stained-Glass Window. (Byzantine Medicine, 476–1453).” International Record of Medicine and General Practice Clinics 173 (January1960): 74–77.
  176. ———. “The Epic of Medicine, VII. The Cross and the Eagle. (Monastic and University Medicine, 1096–1453).” International Record of Medicine and General Practice Clinics 173 (July 1960): 462–67.
  177. ———. “The Fabric and Creation of a Dream: On the Genesis and Growth of a New Concept in Medical Journalism as Exemplified by the Medical Newsmagazine, MD.” International Record of Medicine and General Practice Clinics 172 (December 1959): 754–65.
  178. ———. “A Footnote to Medical History: Concerning the Article by Hans Selye on ‘Stress and Disease.’ ” International Record of Medicine and General Practice Clinics 168, no. 5 (May 1955): 288–91.
  179. ———. “Friends for the Road.” International Record of Medicine and General Practice Clinics 172, no. 8 (August 1959): 480–83.
  180. ———. “The History of Endocrinology as Seen through the Evolution of Our Knowledge of the Adrenal Gland; Biography of a Medical Idea.” International Record of Medicine and General Practice Clinics 165, no. 12 (December 1952): 587–602.
  181. ———. “Life and Works of Paul Ehrlich, 1854–1915; the World and Mind of the Father of Chemotherapy.” Revista Médica de la Universidad de Costa Rica 13, no. 240 (April 1954): 73–87.
  182. ———. “Medicine in the Spain of Don Quixote.” International Record of Medicine and General Practice Clinics 171, no. 5 (May 1958): 277–313.
  183. ———. “Minerva and Aesculapius; the Physician as Writer.” International Record of Medicine and General Practice Clinics 169, no. 11 (November 1956): 723–45.
  184. ———. “New Perspectives of Health and Travel; a Summation of the Symposium.” International Record of Medicine and General Practice Clinics 168, no. 9 (September 1955): 583–86.
  185. ———. “Padna and London; a Harveian Tale of Two Cities.” International Record of Medicine and General Practice Clinics 170, no. 6 (June 1957): 286–316.
  186. ———. “The Physician as Alchemist; Medical Ideas in the Arabian Empire.” International Record of Medicine and General Practice Clinics 168, no. 6 (June 1955): 399–424.
  187. ———. “The Physician as Traveler; Introduction to the First International Symposium on Health and Travel.” International Record of Medicine and General Practice Clinics 168, no. 7 (July 1955): 480–85.
  188. ———. “The Search for the Philosophical Nature of Disease in the History of Medicine; an Introduction to Hans Selye’s Sketch for a Unified Theory of Medicine.” International Record of Medicine and General Practice Clinics 167, no. 4 (April 1954): 179–80.
  189. ———. “Symbols and Medicine.” International Record of Medicine and General Practice Clinics 173, no. 99 (February 1960): 99–125.
  190. ———. “Symposium on the History of American Medicine, I. The Spirit of American Medicine.” International Record of Medicine and General Practice Clinics 171, no. 6 (June 1958): 317–22.
  191. ———. “Words and Research.” Antibiotic Medicine and Clinical Therapy 4, no. 11 (New York: November 1957): 740–47.
  192. Martin, Douglas. “James L. Goddard, Crusading FDA Leader, Dies at 86.” The New York Times, January 2, 2010.
  193. Martin, W. R., C. G. Eades, J. A. Thompson, R. E. Huppler, and P. Gilbert. “The Effects of Morphine- and Nalorphine-Like Drugs in the Nondependent and Morphine-Dependent Chronic Spinal Dog.” Journal of Pharmacology and Experimental Therapeutics (1976).
  194. Max, M. B. “Improving Outcomes of Analgesic Treatment: Is Education Enough?” Annals of Internal Medicine 113, no. 11 (December 1990).
  195. May, Charles D. “Selling Drugs by ‘Educating’ Physicians.” The Journal of Medical Education 36, no. 1 (January 1961).
  196. Mayo, Caswell, and Keenan Thomas. “American Druggist and Pharmaceutical Record: A Semi-Monthly Illustrated Journal of Practical Pharmacy.” New York: American Druggist Publishing Co.: 1906–1907.
  197. McEvilla, Joseph D. “Competition in the American Pharmaceutical Industry.” PhD diss., University of Pittsburgh, 1955.
  198. McFadyen, Richard E. “Estes Kefauver and the Drug Industry.” PhD diss., Emory University, 1973.
  199. ———. “The FDA’s Regulation and Control of Antibiotics in the 1950s: The Henry Welch Scandal, Félix Martí-Ibáñez, and Charles Pfizer & Co.” Bulletin of the History of Medicine 53, no. 2 (Summer 1979).
  200. McGibney, David. “The Future of the Pharmaceutical Industry.” RSA Journal 147, no. 5489 (1999).
  201. McLean, Bethany. “We Didn’t Cause the Crisis.” Vanity Fair, August 2019.
  202. Meed, Steven, Phyllis M. Kleinman, and Thomas G. Kantor. “Management of Cancer Pain with Oral Controlled-Release Morphine Sulfate.” American College of Clinical Pharmacology (February 1987).
  203. Meier, Barry. “At Painkiller Trouble Spot, Signs Seen as Alarming Didn’t Alarm Drug’s Maker.” The New York Times, December 10, 2001.
  204. ———. “Opioid Makers Are the Big Winners in Lawsuit Settlements.” The New York Times, December 26, 2018.
  205. ———. “Origins of an Epidemic: Purdue Pharma Knew Its Opioids Were Widely Abused.” The New York Times, May 29, 2018.
  206. ———. “Why Drug Company Executives Haven’t Really Seen Justice for Their Role in the Opioid Crisis.” Time, June 15, 2018.
  207. Meier, Barry, and Melody Petersen. “Sales of Painkiller Grew Rapidly, But Success Brought a High Cost.” The New York Times, March 5, 2011.
  208. Melzack, Ronald. “The Tragedy of Needless Pain.” Scientific American 262, no. 2 (February 1990).
  209. Mikami, Koichi. “Orphans in the Market: The History of Orphan Drug Policy.” Social History of Medicine 32, no. 3 (August 2019).
  210. Mintz, Morton. “ ‘Heroine’ of FDA Keeps Bad Drug Off Market.” The Washington Post, July 15, 1962.
  211. Morone, Natalia E., and Debra K. Weiner. “Pain as the Fifth Vital Sign: Exposing the Vital Need for Pain Education.” Clinical Therapeutics 35, no. 11 (2013).
  212. Morrell, Alex. “The OxyContin Clan: The $14 Billion Newcomer to Forbes’ 2015 List of Richest U.S. Families.” Forbes, July 1, 2015.
  213. Mosher, H. “Portrayal of Women in Drug Advertising: A Medical Betrayal.” Journal of Drug Issues (1976).
  214. Munch, James C., and James C. Munch Jr. “Notices of Judgment—the First Thousand.” Food Drug Cosmetic Law Journal 10 (1955).
  215. Musto, David F. “An Historical Perspective on Legal and Medical Responses to Substance Abuse.” Villanova Law Review 18 (May 1973): 808–17.
  216. Nagendrappa, Gopalpur. “Yellapragada SubbaRow: The Man of Miracle Drugs.” Resonance (June 2012).
  217. Nahas, G. G., and A. Greenwood. “The First Report of the National Commission on Marihuana (1972): Signal of Misunderstanding or Exercise in Ambiguity.” Bulletin of the New York Academy of Medicine 50, no. 1 (1974).
  218. Nathanson, Neal, and Alexander D. Langmuir. “The Cutter Incident. Poliomyelitis Following Formaldehyde-Inactivated Poliovirus Vaccination in the United States during the Spring of 1955: I and 2. Background.” American Journal of Epidemiology 78, no. 1 (July 1, 1963).
  219. ———. “Thalidomide in America: A Brush with Tragedy.” Clio Medica 11 (Spring 1976): 79–93.
  220. Nelson, M. L., and S. B. Levy. “The History of the Tetracyclines.” Annals of the New York Academy of Sciences 1241 (2011): 17–32.
  221. Nelson, Valerie J. “Dr. James L. Goddard: 1923–2009.” Chicago Tribune, August 25, 2018.
  222. Neushul, Peter. “Science, Government, and the Mass Production of Penicillin.” Journal of the History of Medicine and Allied Sciences 48 (October 1993).
  223. Neustadt, R. E., and H. V. Fineberg. “The Swine Flu Affair: Decision-Making on a Slippery Disease.” D, Selected Documents. (Washington, DC: National Academies Press: 1978).
  224. Nevius, James. “The Strange History of Opiates in America: From Morphine for Kids to Heroin for Soldiers.” The Guardian, March 15, 2016.
  225. Norberg, Peter, Maria Bergström, Vinay Jethava, Devdatt Dubhashi, and Malte Hermansson. “The IncP-1 Plasmid Backbone Adapts to Different Host Bacterial Species and Evolves through Homologous Recombination.” Nature Communications 2 (2011): 272.
  226. Palo, Nishit, et al. “Effects of Osteoarthritis on Quality of Life in Elderly Population of Bhubaneswar, India: A Prospective Multicenter Screening and Therapeutic Study of 2,854 Patients.” Geriatric Orthopaedic Surgery & Rehabilitation 6, no. 4 (2015): 269–75.
  227. Papadopoulos, Stelios. “Evolving Paradigms in Biotech IPO Valuations.” Nature Biotechnology 19 (2001): BE18–19.
  228. Parker-Pope, Tara. “Drug Resistance, Explained.” The New York Times, March 27, 2008.
  229. Parthasarathy, R. “Discoverer of Miracle Medicines.” “Science and Technology.” The Hindu, March 13, 2003.
  230. Perch, Michael Morten Sodemann, Marianne S. Jakobsen, Palle Valentiner-Branth, Hans Steinsland, Thea K. Fischer, Dina Duarte Lopes, Peter Aaby, and Kåre Mølbak. “Seven Years’ Experience with Cryptosporidium Parvum in Guinea-Bissau, West Africa.” Annals of Tropical Paediatrics 21, no. 4 (2001).
  231. Perrone, Matthew, and Ben Wieder. “Pro-Painkiller Echo Chamber Shaped Policy Amid Drug Epidemic,” Part 2 of 3. The Center for Public Integrity, copublished with The Associated Press, September 19, 2016.
  232. Perrone, Matthew, Liz Essley Whyte, and Geoff Mulvihill. “Drugmakers Push Profitable, but Unproven, Opioid Solution,” Part 3 of 3. The Center for Public Integrity, copublished with The Associated Press, December 15, 2016. See under Liz Essley Whyte for Part 1.
  233. Pestka, Sidney. “The Interferons: 50 Years after Their Discovery, There Is Much More to Learn.” The Journal of Biological Chemistry 282, no. 28 (July 13, 2007).
  234. Pisano, Gary P. “Can Science Be a Business?: Lessons from Biotech.” Harvard Business Review, October 2006.
  235. Plunkett, Matthew J., and Jonathan A. Ellman. “Combinational Chemistry and New Drugs.” Scientific American, April 1997.
  236. Podolsky, Scott H. “Antibiotics and the Social History of the Controlled Clinical Trial, 1950–1970.” Journal of the History of Medicine and Allied Sciences 65, no. 3 (2010): 327–67.
  237. Podolsky, Scott H., and J. A. Greene. “Keeping Modern in Medicine: Pharmaceutical Promotion and Physician Education in Postwar America.” Bulletin of the History of Medicine 83, no. 2 (Summer 2009).
  238. Portenoy, R. K. “Appropriate Use of Opioids for Persistent Non-Cancer Pain.” The Lancet 364, no. 9436 (2004): 739–74.
  239. ———. “The Use of Opioids for the Treatment of Chronic Pain.” The Journal of Pain 6, no. 1 (Spring 1997): 77–79.
  240. Portenoy, R. K., and K. M. Foley. “Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases.” Pain 25, no. 2 (May 1986): 171–86.
  241. Prather, J., and L. Fidel. “Sex Differences in the Content and Style of Medical Advertisements.” Social Science & Medicine (1975).
  242. Quest, T. L., J. O. Merrill, J. Roll, A. J. Saxon, and R. A. Rosenblatt. “Buprenorphine Therapy for Opioid Addiction in Rural Washington: The Experience of the Early Adopters.” Journal of Opioid Management 8 (2012): 29–38.
  243. Quianzon, Celeste C., and Issam Cheikh. “History of Insulin.” Journal of Community Hospital Internal Medicine Perspectives 2, no. 2 (2012).
  244. Quinn, Roswell. “Rethinking Antibiotic Research and Development: World War II and the Penicillin Collaborative.” American Journal of Public Health 103, no. 3 (2013).
  245. Ransom, Alicia Burnett. “Direct-to-Physician Advertising, Depression, and the Advertised Female Patient.” PhD diss., University of Tennessee, 2017.
  246. Rao, T. S. Sathyanarayana, and Chittaranjan Andrade. “MMR Vaccine and Autism: Sensation, Refutation, Retraction, and Fraud.” Indian Journal of Psychiatry 53, no. 2 (2011).
  247. Rasmussen, Nicolas. “America’s First Amphetamine Epidemic 1929–1971; A Quantitative and Qualitative Retrospective with Implications for the Present.” American Journal of Public Health (June 2008).
  248. Regier, C. C. “The Struggle for Federal Food and Drugs Legislation.” Law and Contemporary Problems 1, no. 1 (1933).
  249. Reynolds, Preston P. “Dr. Louis T. Wright and the NAACP: Pioneers in Hospital Racial Integration.” American Journal of Public Health 90, no. 6 (June 2000).
  250. Rheingold, Paul D. “The MER/29 Story—an Instance of Successful Mass Disaster Litigation.” California Law Review 56, no. 1 (1968).
  251. Rheingold, Paul D., and Clifford J. Shoemaker. “The Swine Flu Litigation.” Litigation 8, no. 1 (1981).
  252. Rickels, K., et al. “Controlled Psychopharmacological Research in Private Psychiatric Practice.” Psychopharmacologia 9, no. 4 (1966).
  253. Rita, R. “Court Upholds Injunction on Sale of Sackler Art.” The New York Times, January 7, 1993.
  254. Romm, Cari. “ ‘The Disease of the Century’: Reporting on the Origin of AIDS.” The Atlantic, December 5, 2014.
  255. Rosenbaum, Lee. “The Met’s Sackler Enclave: Public Boon or Private Preserve?” ARTnews, September 1978, 56–57.
  256. Rosenberg, Charles, and Carroll Smith-Rosenberg. “The Female Animal: Medical and Biological Views of Woman and Her Role in Nineteenth-Century America.” Journal of American History (1973): 60.
  257. Rosenblum, Andrew, Lisa A. Marsch, Herman Joseph, and Russell K. Portenoy. “Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions.” Experimental and Clinical Psychopharmacology 16, no. 5 (2008): 405–16.
  258. Ruge, R. B. “Regulation of Prescription Drug Advertising: Medical Progress and Private Enterprise.” Publishing Entertainment Advertising Law Quarterly 9, no. 3 (1969): 261–99.
  259. Ruoff, K. L. “Miscellaneous Catalase-Negative, Gram-Positive Cocci: Emerging Opportunists.” Journal of Clinical Microbiology 40, no. 4 (2002): 1129–33.
  260. Ryan, Harriet, Lisa Girion, and Scott Glover. “OxyContin Goes Global—‘We’re Only Just Getting Started,’ ” Los Angeles Times, December 18, 2016.
  261. ———.“ ‘You Want a Description of Hell?’ Oxycontin’s 12-Hour Problem.” Los Angeles Times, May 5, 2016.
  262. Ryan, Kenneth J. “Cancer Risk and Estrogen Use in the Menopause.” The New England Journal of Medicine (December 4, 1975): 293.
  263. Sackler, A. M. “Taboos of the Past and Perspectives for the Future in Social Psychiatry.” International Journal of Social Psychiatry 19, nos. 1–2 (1973): 4–9.
  264. Sackler, Arthur M., and Lawrence H. Sophian. “The Effects of the Ingestion of Amino Acid on Gastric Secretion, with Particular Reference to L-Lysine Monohydrochloride.” American Journal of Clinical Pathology 28, no. 3 (September 1, 1957): 258–63.
  265. Sackler, M., F. Martí-Ibáñez, R. Sackler, and A. Sackler. “The Challenge of Bio- and Chemotherapy in Psychiatry.” The Journal of Clinical and Experimental Psychopathology 17, no. 1 (January–March 1956): 15–18.
  266. ———. “Contemporary Physiodynamic Therapeutic Trends in Psychiatry.” The Journal of Clinical and Experimental Psychopathology 15, no. 4 (October–December 1954): 382–400.
  267. ———. “Neuroendocrinologic Basis for a Metabolic Concept of Several Psychiatric Disorders.” International Record of Medicine and General Practice Clinics 166, no. 3 (March 1953): 81–90.
  268. ———. “On Tolerance to and Craving for Alcohol in Histamine-Treated Schizophrenics; A Physiodynamic Interpretation of Observations on Histamine-Adrenocortico-Hormonal Equilibrations.” The Psychiatric Quarterly 26, no. 4 (October 1952): 597–607.
  269. ———. “The Philosophy of Organicism in Psychiatry.” The Journal of Clinical and Experimental Psychopathology 15, no. 3 (July–September 1954): 179–90.
  270. ———. “Psychiatric Implications of Sex Differences in Thyroid-Histamine Interrelationship; A Clinical and Laboratory Study.” The Journal of Clinical and Experimental Psychopathology 17, no. 3 (July–September 1956): 297–307.
  271. ———. “Quantitated Identification of Psychosis by Blood Sample, I. Instrumentation of Ultrasound for Biologic Quantitation.” The Journal of Clinical and Experimental Psychopathology 12, no. 4 (October–December 1951): 283–87.
  272. ———. “Quantitated Identification of Psychosis by Blood Sample, II. Ultrasonometry: A New Modality in Biology and Medicine.” The Journal of Clinical and Experimental Psychopathology 12, no. 4 (October–December 1951): 288–303.
  273. ———. “Quantitated Identification of Psychosis by Blood Sample, III. Ultrasonometry: A New Modality in Biology and Medicine.” The Journal of Clinical and Experimental Psychopathology 12, no. 4 (October–December 1951): 304–22.
  274. ———. “The Quest for Freud.” The Journal of Clinical and Experimental Psychopathology 17, no. 2 (April–June 1956): 117–27.
  275. ———. “Tests for Pathophysiologic Identification and Classification of Psychoses.” The Journal of Clinical and Experimental Psychopathology 19, no. 1 (January–March 1958): 1–6.
  276. ———. “Theory and the Future of Research in Psychiatry.” The Journal of Clinical and Experimental Psychopathology 18, no. 4 (October–December 1957): 319–22.
  277. ———. “Toward a Unifying Concept in Psychiatry.” The Journal of Clinical and Experimental Psychopathology 19, no. 2, S1 (April–June 1958): i–iv.
  278. Sackler, M. D., et al. “Psychiatric Research Perspectives at the Creedmoor Institute for Psychobiologic Studies.” Journal of Clinical Experimental Psychopathology 15, no. 2 (April–June 1954): 119–29.
  279. Sackler, R. R., et al. “Eosinophile Levels in Hospitalized Psychotics during Combined Testosterone-Estrogen Therapy.” Proceedings of the Society for Experimental Biology and Medicine 76, no. 2 (1951).
  280. Sarayloo, Kimiya. “A Poor Man’s Tale of Patented Medicine: The 1962 Amendments, Hatch-Waxman, and the Lost Admonition to Promote Progress.” Quinnipiac Health Law Journal 18 (2015).
  281. Saunders, C. “The Treatment of Intractable Pain in Terminal Cancer.” Proceedings of the Royal Society of Medicine 56, no. 3 (1963).
  282. Schatz, Albert, Elizabeth Bugie, and Selman Waksman. “Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.” Proceedings of the Society for Experimental Biology and Medicine 55 (1944).
  283. Schechtman, Leonard M. “The Safety Assessment Process—Setting the Scene: An FDA Perspective.” ILAR Journal 43, no. 1 (January 2002).
  284. Scherer, F. M. “The F.T.C., Oligopoly, and Shared Monopoly.” Faculty Research Working Paper Series, Harvard Kennedy School, RWP13-031, September 2013.
  285. Scherer, F. M., and William S. Comanor. “Mergers and Innovation in the Pharmaceutical Market.” Faculty Research Working Paper Series, Harvard Kennedy School, RW11-043, November 2011.
  286. Schmeck, Harold M. “Congress Votes Flu Vaccine Liability Bill.” The New York Times, August 11, 1976.
  287. Schneider, A. Patrick, Christine M. Zainer, Christopher Kevin Kubat, Nancy K. Mullen, and Amberly K. Windisch. “The Breast Cancer Epidemic: 10 Facts.” The Linacre Quarterly 81, no. 3 (2014).
  288. Schobelocka, Michael J., et al., “Multiple-Dose Pharmacokinetic Evaluation of Two Formulations of Sustained-Release Morphine Sulfate Tablets.” Current Therapeutic Research 56, no. 10 (October 1995).
  289. Scholl, L., P. Seth, M. Kariisa, N. Wilson, and G. Baldwin. “Drug and Opioid-Involved Overdose Deaths—United States, 2013–2017.” Morbidity and Mortality Weekly Report (2019): 67.
  290. Schulte, Fred. “How America Got Hooked on a Deadly Drug.” “Kaiser Health News.” The Washington Post, June 13, 2018.
  291. Schulte, Fred, and Nancy McVicar. “OxyContin Ads Were Aggressive, Records Show.” Florida Sun-Sentinel, February 21, 2003.
  292. ———. “OxyContin Was Touted as Virtually Nonaddictive, Newly Released State Records Show.” Florida Sun-Sentinel, March 6, 2003.
  293. Schwartz, L. M., and S. Woloshin. “Medical Marketing in the United States, 1997–2016.” JAMA 321, no. 1 (2019): 80–96.
  294. Schwartzman, David. “Innovation in the Pharmaceutical Industry.” (Baltimore, MD: Johns Hopkins Press, 1976).
  295. “SciTech Tuesday: Sir Alexander Fleming’s Ominous Prediction.” See & Hear, The National WWII Museum blog, January 11, 2017.
  296. Scroop, Daniel. “A Faded Passion? Estes Kefauver and the Senate Subcommittee on Antitrust and Monopoly.” Business History Conference 5 (2007).
  297. Sencer, David J., and J. Donald Millar. “Reflections on the 1976 Swine Flu Vaccination Program.” FDA Consumer 12, no. 1 (January 2006).
  298. Severo, Richard. “Impoverished Haitians Sell Plasma for Use in the U.S.” The New York Times, January 28, 1972.
  299. Shah, Manish S., Erin R. Holmes, and Shane P. Desselle. “The Use of Persuasion in Print DTC Advertisements of Prescription Drugs: A Content Analysis of Leading Consumer Magazines from 1995–2000.” Journal of Pharmaceutical Marketing & Management 15, no. 3 (2003): 23–43.
  300. Shapiro, Edward S. “Jews with Money.” Judaism 36, no. 1 (Winter 1987).
  301. Sharp, Paul M., and Beatrice H. Hahn. “Origins of HIV and the AIDS Pandemic.” Cold Spring Harbor Perspectives in Medicine 1, no. 1 (2011).
  302. Sharp, Paul M., et al. “Origins and Evolution of AIDS Viruses: Estimating the Time-Scale.” Biochemical Society Transactions 28, no. 2 (February 1, 2000): 275–82.
  303. Shorter, Edward. “The Liberal State and the Rogue Agency: FDA’s Regulation of Drugs for Mood Disorders, 1950s–1970s.” International Journal of Law and Psychiatry 31, no. 2 (2008): 126–35.
  304. Siegel, Ronald K. “Repeating Cycles of Cocaine Use and Abuse.” In Treating Drug Problems, Volume 2: Commissioned Papers on Historical, Institutional, and Economic Contexts of Drug Treatment. Institute of Medicine, Committee for the Substance Abuse Coverage Study. (Washington, DC: The National Academies Press, 1992.)
  305. Simons, J. “Lilly Goes Off Prozac: The Drugmaker Bounced Back from the Loss of Its Blockbuster, but the Recovery Had Costs.” Fortune, June 28, 2004.
  306. Smith, Michael J., Susan S. Ellenberg, Louis M. Bell, and David M. Rubin. “Media Coverage of the Measles-Mumps-Rubella Vaccine and Autism Controversy and Its Relationship to MMR Immunization Rates in the United States.” Pediatrics 121, no. 4, e836–43 (April 2008).
  307. Smith, Mickey C., and Lisa Griffin. “Rationality of Appeals Used in the Promotion of Psychotropic Drugs.” Social Science & Medicine (1977).
  308. Sneader, Walter. “The Discovery of Heroin.” The Lancet 352, no. 914 (1998).
  309. Snyder, Solomon H. “Arthur M. Sackler and Science.” Proceedings of the National Academy of Sciences of the United States of America 98, no. 20 (2001).
  310. So, Anthony D., Neha Gupta, and Otto Cars. “Tackling Antibiotic Resistance: Concerted Action Is Needed to Provide New Technologies and Conserve Existing Drugs.” The BMJ 340, no. 7756 (2010): 1091–92. http://www.jstor.org/stable/40702199.
  311. Speaker, Susan L. “From ‘Happiness Pills’ to ‘National Nightmare’: Changing Cultural Assessment of Minor Tranquilizers in America, 1955–1980.” Journal of the History of Medicine and Allied Sciences 52, no. 3 (July 1, 1997).
  312. Steele, Henry. “The Fortunes of Economic Reform Legislation: The Case of the Drug Amendments Act of 1962.” The American Journal of Economics and Sociology 25, no. 1, January 1966.
  313. Steere, A. C., et al. “Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant.” The New England Journal of Medicine (1998): 339. https://www.nejm.org/doi/full/10.1056/NEJM199807233390401.
  314. Stengren, Bernard. “He Takes Pulse of 150,000 U.S. Physicians.” St. Louis Post-Dispatch, June 13, 1960.
  315. Sternbach, Leo H. “The Benzodiazepine Story.” Journal of Medicinal Chemistry 22 (1979): 1–7.
  316. ———. “The Discovery of Librium.” Agents and Actions 2, no. 4 (1972).
  317. Sullivan, Mark D., and B. Ferrell. “Ethical Challenges in the Management of Chronic Nonmalignant Pain: Negotiating through the Cloud of Doubt.” The Journal of Pain 6, no. 1 (2005): 2–9.
  318. Sullivan, Mark D., and Catherine Q. Howe. “Opioid Therapy for Chronic Pain in the United States: Promises and Perils.” Pain 154, no. S1 (2013).
  319. Tanne, Janice Hopkins. “Fighting AIDS: On the Front Lines Against the Plague.” The New York Times Magazine, January 12, 1987.
  320. Tomer, Adam. “The Secret Life of the Gay Jewish Immigrant Whose Company Sells Your Medical Information.” The Forward, January 12, 2017.
  321. Temin, Peter. “The Evolution of the Modern Pharmaceutical Industry.” Working paper no. 223, Department of Economics, Massachusetts Institute of Technology, 1978.
  322. Tuck, Lon. “Dr. Arthur Sackler: Art and Frustrations.” The International Herald Tribune, September 27–28, 1986.
  323. Urdang, George. “The Antibiotics and Pharmacy.” Journal of the History of Medicine and Allied Sciences 6, no. 3 (1951).
  324. “U.S. False Ad Drive Cites Journal of AMA.” Los Angeles Times, March 4, 1966.
  325. Valium Mainstream Health Alerts: “Tired? Nervous? Here’s a Pill.” McCall’s, April 1973; “Danger Ahead! Valium—The Pill You Love Can Turn On You.” Vogue, February 1975; Nolen, William. “Tranquilizer Use and Abuse.” McCall’s, May 1976; “What’s Good about Tranquilizers?” Vogue, April 1976.
  326. Vallely, Paul. “Drug That Spans the Ages: The History of Cocaine.” The Independent (UK), March 2, 2006.
  327. Van Boeckel, Thomas P., et al. “Reducing Antimicrobial Use in Food Animals.” Science 357, no. 6358 (September 29, 2017): 1350–52.
  328. Van Miert, A. S. “The Sulfonamide-Diaminopyrimidine Story.” Journal of Veterinary Pharmacology and Therapeutics 17 (1994): 309–16.
  329. Van Zee, A. “The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy.” American Journal of Public Health 99, no. 2 (2009).
  330. “VA’s Opiate Overload Feeds Veterans’ Addictions, Overdose Deaths.” The Center for Investigative Reporting, September 28, 2013.
  331. Wainwright, Milton. “Streptomycin: Discovery and Resultant Controversy.” History and Philosophy of the Life Science 13, no. 1 (1991).
  332. Wakefield, A. J., et al. “Ileal-Lymphoid-Nodular Hyperplasia, Nonspecific Colitis, and Pervasive Developmental Disorder in Children.” The Lancet 351, no. 9103 (February 28, 1998): 637–41.
  333. Wakefield, Anne E. “Biology of Plagues: Evidence from Historical Populations.” 1st Edition, by Susan Scott, Christopher J. Duncan.
  334. ———. “Pneumocystis carinii Role in Childhood Respiratory Infections.” British Medical Bulletin 61, no. 1 (March 1, 2002).
  335. Wallace, Mike. “Swine Flu.” CBS 60 Minutes, November 4, 1979.
  336. Walters, Joanna. “America’s Opioid Crisis: How Prescription Drugs Sparked a National Trauma.” The Guardian, October 25, 2017.
  337. Wanzer, Sidney H., et al. “The Physician’s Responsibility Toward Hopelessly Ill Patients.” The New England Journal of Medicine (March 30, 1989).
  338. Watanabe, Myrna. “AIDS 20 Years Later.” The Scientist, June 11, 2001.
  339. Watkins, Elizabeth Siegel. “How the Pill Became a Lifestyle Drug: The Pharmaceutical Industry and Birth Control in the United States Since 1960.” American Journal of Public Health 102, no. 8 (August 2012): 1462–72.
  340. Watson, Bruce. “The Poison Squad: An Incredible History.” Esquire, June 27, 2013.
  341. Webster, L. R., and P. G. Fine. “Approaches to Improve Pain Relief While Minimizing Opioid Abuse Liability.” The Journal of Pain 11, no. 7 (2010): 602–11.
  342. Weinberg, Alvin M. “Impact of Large Scale Science on the United States.” Science 134, no. 3473 (July 21, 1961).
  343. Weinstein, Louis. “The Spontaneous Occurrence of New Bacterial Infections during the Course of Treatment with Streptomycin or Penicillin.” American Journal of Medical Science 214 (1947).
  344. Weisberger, Bernard A. “Doctor Wiley and His Poison Squad.” American Heritage 47, no. 1 (February/March 1996).
  345. Weissman, D., and David J. Haddox. “Opioid Pseudoaddiction—an Iatrogenic Syndrome.” Pain 36, no. 3 (March 1989).
  346. White, G. C. “Hemophilia: An Amazing 35-Year Journey from the Depths of HIV to the Threshold of Cure.” Transactions of the American Clinical and Climatological Association 121 (2010): 61–73; discussion S74–5.
  347. Whitebread, Charles. “The History of Non-Medical Use of Drugs in the United States.” Journal of Cognitive Liberties (Fall 2000).
  348. Whyte, Liz Essley, Geoff Mulvihill, and Ben Wieder. “Politics of Pain: Drugmakers Fought State Opioid Limits Amid Crisis,” part 1 of 1. The Center for Public Integrity, copublished with The Associated Press, September 18, 2016.
  349. Winn, Thomas J. “The Antibiotics Market.” Drug and Cosmetic Industry 67 (1950).
  350. Winslow, Charles-Edward A. “The Conquest of Epidemic Diseases: A Chapter in the History of Ideas.” (Princeton, NJ: Princeton University Press, 1943).
  351. Wirtschafter, Jonathan Dine. “The Genesis and Impact of the Medical Lobby: 1898–1906.” Journal of the History of Medicine and Allied Sciences 13, no. 1 (January 1958).
  352. Wistrand-Yuen, Erik, et al. “Evolution of High-Level Resistance during Low-Level Antibiotic Exposure.” Nature Communications 9, no. 1 (2018).
  353. Wolfram, Charles W. “The Antibiotics Class Actions.” American Bar Foundation Research Journal 1, no. 1 (1976): 251–363.
  354. Wong, Stacy. “Thrust Under Microscope: Stamford Drug Company’s Low Profile Shattered by Controversy over Abuse of Painkiller OxyContin.” Hartford Courant (New Haven, CT), September 2, 2001.
  355. Wood, Donna. “The Strategic Use of Public Policy: Business Support for the 1906 Food and Drug Act.” The Business History Review 59, no. 3 (Autumn 1985).
  356. Worley, John K. “Problems of Compliance with the Drug Amendments of 1962.” The Business Lawyer 19, no. 1 (1963).
  357. Worobey, M., et al. “Direct Evidence of Extensive Diversity of HIV-1 in Kinshasa by 1960.” Nature 455, no. 7213 (2008): 661–64.
  358. Yasmin, Seema, and Madhusree Mukerjee. “The Dengue Debacle.” Scientific American, April 2019.
  359. Young, James Harvey, and George Griffenhagen. “Old English Patent Medicines in America.” Chemist and Druggist (London), June 29, 1957.
  360. Yuli, Yang. “U.S. Doctor’s Generosity to China.” Beijing Review, May 13–19, 1992.
  361. Zajac, V. “Evolutionary View of the AIDS Process.” The Journal of International Medical Research 46, no. 10 (2018): 4032–38.
  362. Zhang, Sarah. “The One-Paragraph Letter from 1980 That Fueled the Opioid Crisis.” The Atlantic, June 2, 2017.
  363. Zhu, T., B. Korber, A. Nahmias, E. Hooper. P. M. Sharp, and D. D. Ho. “An African HIV-1 Sequence from 1959 and Implications for the Origin of the Epidemic.” Nature 391, no. 6667 (February 1998): 594–97.
  364. Ziporyn, Terra. “The Food and Drug Administration: How ‘Those Regulations’ Came to Be.” Journal of the American Medical Association 254 (1985).

Government Hearings and Publications

  1. Administered Drug Prices: Report of the Committee on the Judiciary, Subcommittee on Antitrust and Monopoly, pursuant to S. Red. 52, to Study the Antitrust Laws of the United States and Their Interpretation, Study of the Administered Prices in the Drug Industry. 87th Cong., 1st sess. (Washington, D.C.: U.S. Government Printing Office, 1961).
  2. Administered Prices Hearings before the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, U.S. Senate, 86th Cong., 2nd sess., part 23 (Washington, D.C.: U.S. Government Printing Office, 1957).
  3. Alcohol, Drug Abuse, and Mental Health Administration. National Institute on Drug Abuse Division of Research.
  4. Benzodiazepines: A Review of Research Results. Ed. oversight Stephen I. Szara and Jacqueline P. Ludford. National Institute on Drug Abuse, NIDA Research Monograph 33 A RAUS Review Report, Department of Health and Human Services Public Health Service.
  5. Biomedical Politics. Division of Health Sciences Policy Committee to Study Biomedical Decision Making, Institute of Medicine. (Washington, D.C.: The National Academies Press, 1991).
  6. Decisions of Courts in Cases under the Federal Food and Drugs Act. Full text, vol.1 (Washington, D.C.: U.S. Government Printing Office, 1934).
  7. Economic Report on Antibiotics Manufacture. Federal Trade Commission. (Washington, DC: U.S. Government Printing Office, 1958).
  8. Evaluating the Propriety and Adequacy of the Oxy-Contin Criminal Settlement Hearing Before the Committee on the Judiciary, U.S. Senate, 110th Cong., 1st sess. (July 31, 2007). (Washington, D.C.: U.S. Government Printing Office, 2008).
  9. “Examination of the Pharmaceutical Industry, 1973–74.” Committee on Labor and Public Welfare. Hearings Before the Subcommittee on Health, 93rd Cong., 1st and 2nd sess., 1973–1974, part 3.
  10. “Foods and Food Adulterants: Dairy Products,” vol. 1, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: Government Printing Office, 1887).
  11. “Foods and Food Adulterants: Spices and Condiments,” vol. 2, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1887).
  12. “Foods and Food Adulterants: Fermented Alcoholic Beverages, Malt Liquors, Wine, and Cider,” vol. 3, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1887).
  13. “Foods and Food Adulterants: Lard and Lard Adulteration,” vol. 4, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1889).
  14. “Foods and Food Adulterants: Baking Powder,” vol. 5, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1889).
  15. “Foods and Food Adulterants: Sugar, Molasses and Sirup, Confections, Honey and Beeswax,” vol. 6, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1892).
  16. “Foods and Food Adulterants: Tea, Coffee, and Cocoa Preparations,” vol. 7, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1892).
  17. “Foods and Food Adulterants: Canned Vegetables,” vol. 8, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1893).
  18. “Foods and Food Adulterants: Cereals and Cereal Products,” vol. 9, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1898).
  19. “Foods and Food Adulterants: Preserved Meats,” vol. 10, no. 13, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1902).
  20. “Foods and Food Control,” (W. D. Bigelow, chief, Division of Foods), U.S. Department of Agriculture, Bureau of Chemistry, revised to July 1, 1905 (Washington, D.C.: U.S. Government Printing Office, 1905).
  21. Freer, Robert E., chairman, Federal Trade Commission, “Truth in Advertising (with Specific Relation to the Broadcasting Industry),” talk before the Radio Executives Club of New York, November 20, 1944.
  22. Hearings Before the Committee on Interstate and Foreign Commerce of the House of Representatives on the Pure-Food Bills H.R. 3044, 4527, 7018, 12071, 13086, 13853, and 13859, for Preventing the Adulteration, Misbranding, and Imitation of Foods, Beverages, Candies, Drugs, and Condiments in the District of Columbia and the Territories, and for Regulating Interstate Traffic Therein, and for Other Purposes, 59th Cong., 1st sess., House Committee on Interstate and Foreign Commerce (Washington, D.C.: U.S. Government Printing Office, January 1, 1906).
  23. Hussey, H. H. Statement of the American Medical Association Re: S.1552, 87th Cong. Drug Industry Antitrust Act. JAMA 177, no. 3 (1961): 190–95.
  24. “Influence of Food Preservatives and Artificial Colors on Digestion and Health: Boric Acid and Borax,” vol. 1, no. 84, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1904).
  25. “Influence of Food Preservatives and Artificial Colors on Digestion and Health: Boric Salicylic Acid and Salicylates,” vol. 2, no. 84, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1906).
  26. “Influence of Food Preservatives and Artificial Colors on Digestion and Health: Sulphurous Acid and Sulphites,” vol. 3, no. 84, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1907).
  27. “Influence of Food Preservatives and Artificial Colors on Digestion and Health: Benzoic Acid and Benzoates,” vol. 4, no. 84, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1908).
  28. “Influence of Food Preservatives and Artificial Colors on Digestion and Health: Formaldehyde,” vol. 5, no. 84, U.S. Department of Agriculture, Division of Chemistry (Washington, D.C.: U.S. Government Printing Office, 1908).
  29. Halcion: An Independent Assessment of Safety and Efficacy Data. Institute of Medicine (US) Committee on Halcion: An Assessment of Data Adequacy and Confidence. (Washington, D.C.: National Academies Press, 1997).
  30. “Incentives and Focus in University and Industrial Research: The Case of Synthetic Insulin”. Institute of Medicine (US) Committee on Technological Innovation in Medicine; N. Rosenberg, A. C. Gelijns, and H. Dawkins, eds. Sources of Medical Technology: Universities and Industry (Washington, DC: National Academies Press, 1995). 7,
  31. Meyers, E. B., ed. Journal of Proceedings of the Seventh Annual Convention of the National Association of State Dairy and Food Departments, vol. 7 (Washington, D.C.: State Dairy and Food Departments, January 1, 1903).
  32. “Prescription Drugs: Oxy-Contin Abuse and Diversion and Efforts to Address the Problem,” GAO-04-110 (Washington, DC: General Accounting Office, December 2003).
  33. “Pulse Check. Trends in Drug Abuse. January-June 2001 Reporting Period. Special Topic: Synthetic Opioids.” (Washington, D.C.: Office of National Drug Control Policy, 2001).
  34. Pure Food Legislation: Hearings Before the Committee on Interstate and Foreign Commerce of the House of Representatives on Bills H.R. 3109, 12348, 9352, 276 and 4342, Poviding [sic] Against the Adulteration or Misbranding of Foods, Beverages, Drugs, Etc., in the District of Columbia and the Territories, and for Regulating Interstate Traffic in Such Products. (Washington, D.C.: U.S. Government Printing Office, January 1, 1902).
  35. “Vaccine Supply and Innovation.” National Research Council (US) Division of Health Promotion and Disease Prevention. Liability for the Production and Sale of Vaccines. (Washington, D.C.: National Academies Press, 1985), 6.

Private Papers and Archival Collections

  1. A. H. Robins Company, Virginia Museum of History & Culture, 1885–2004 (Mss3 R5535a FA2), Virginia Historical Society, Richmond, VA.
  2. American Medical Association, Archives and Manuscripts Division, Chicago, IL.
  3. Bonita, John. Management of Pain and Oral History, History of Pain Collection, University of California at Los Angeles, CA.
  4. Burroughs-Wellcome Papers. Wellcome Library for the History of Medicine, London, England.
  5. The Collection of Louis Tompkins Wright Papers. 1879, 1891–1997, Center for the History of Medicine, Francis A. Countway Library of Medicine, Boston, MA.
  6. Drug Efficacy Study records. National Academy of Sciences Archives, Washington, DC.
  7. Drug Industry Digital Archive. Archives and Special Collections, University of California, San Francisco, Library.
  8. Duggar, Dorothy. “Our Lineage.” Thirteen-page typewritten document about Duggar’s recollections, and details about her grandparents, Dr. Reuben Henry Duggar and Margaret Louisa Minge. Undated, collection of author.
  9. Finland, Maxwell. Papers. Archives and Special Collections, Countway Medical Library, Harvard Medical School, Boston, MA.
  10. Guide to the Communist Party of the United States of America Records. TAM.132, Tamiment Library and Robert F. Wagner Labor Archive, Elmer Holmes Bobst Library, New York, NY.
  11. Kefauver, Estes. Papers. Hoskins Special Collections Library, University of Tennessee, Knoxville, TN.
  12. Lasagna, Louis C. Papers. Department of Rare Books, Special Collections and Preservation, Rush Rhees Library, University of Rochester, NY.
  13. Martí-Ibáñez, Félix. Papers. Yale University Archives, New Haven, CT.
  14. Mayo Foundation History of Medicine Library, Mayo Clinic, Rochester, MI.
  15. Murti, Kasturi Suryanarayana. Transcript of interview by S. P. K. Gupta in Kakinada, India, August 1954; collection of author.
  16. Parke-Davis Regulatory Affairs Office and Company Library, Ann Arbor, MI.
  17. Scherer, F. M. “The F.T.C., Oligopoly, and Shared Monopoly.” Faculty Research Working Paper Series, Harvard Kennedy School, Boston, MA, September 2013.
  18. Upjohn Company records, Kalamazoo Public Library, Kalamazoo, MN.

Government Collections

  1. FDA Library, U.S. Food and Drug Administration, Rockville, MD.
  2. Florey, Howard Walter. Catalog of Papers. “Howard Walter Florey, Baron Florey of Adelaide Pathologist (1898–1968).” Royal Society, London.
  3. Goddard, James L. Papers. History of Medicine Division of the National Library of Medicine, Bethesda, MD.
  4. Harvey Washington Wiley Papers, Library of Congress Manuscript Division, Washington, DC.
  5. John C. Liebeskind History of Pain Collection, History & Special Collections, UCLA Louise M. Darling Biomedical Library, Los Angeles, CA.
  6. Letterbrooks, General Correspondence, Bureau of Chemistry, National Archives.
  7. National Archives and Records Administration. Washington, D.C., and College Park, MD, Records of the FDA, RG 88.
  8. ———. Records of the Secretary of Agriculture, RG 16.
  9. ———. Committee on Manufactures, Records of the Senate, RG 46.
  10. ———. Records of the National Institutes of Health, RG 433.
  11. National Archives of the United Kingdom. Records of the Committee on the Safety of Drugs, Kew, London, UK.
  12. Oral History Collection for the FDA, History of Medicine Division, and Oral History Collection, National Institutes of Health, Historical Office, both at the National Library of Medicine, Bethesda, MD.
  13. Records of the U.S. Department of Health, Education and Welfare (partial). John F. Kennedy Presidential Library, Boston, MA.
  14. Swine Flu, James M. Cannon Files, Gerald R. Ford Presidential Library, University of Michigan, Ann Arbor, MI.
  15. Welch, Dr. Henry. FDA Materials Correspondence (10 of 10), RG 46, National Archives.
  16. Wiley, Anna Kelton. Papers. Coolidge-Consumerism Collection, Manuscript Division, Library of Congress, Washington, D.C.
  17. Wiley, Harvey Washington. Papers. Library of Congress Manuscript Division, Washington, D.C.

Trial Transcripts, Proceedings, Hearings

  1. Administered Prices: Drugs, Report of the Committee on the Judiciary, Subcommittee on Antitrust and Monopoly, 87th Cong., 1st sess. (Washington, D.C.: U.S. Government Printing Office, 1961).
  2. American Cyanamid Company, Petitioner, v. Elliot L. Richardson, Secretary of Health, Education and Welfare, et al., Respondents, 456 F.2d 509, No. 71-1388, United States Court of Appeals, First Circuit, Heard December 14, 1971, Decided December 16, 1971.
  3. Antibiotic Resistance Threats in the United States, CDC (Washington, D.C.: U.S. Government Printing Office, 2013).
  4. Biotechnology Law Report 24, no. 6, Purdue Pharma L. P., The Purdue Frederick Company, The P. F. Laboratories, Inc., and The Purdue Pharma Company and EuroCeltique S.A. v. Endo Pharmaceuticals Inc. and Endo Pharmaceuticals Holdings Inc. (04-1189, 04-1347, 04-1357). Published online: December 8, 2005.
  5. Carter-Wallace, Inc., Petitioner, v. John W. Gardner, Secretary of Health, Education, and Welfare, and James L. Goddard, Commissioner of Food and Drugs, Respondents, 417 F.2d 1086 (4th Cir. 1969), U.S. Court of Appeals for the Fourth Circuit—417 F.2d 1086 (4th Cir. 1969). Argued October 31, 1968. Decided November 4, 1969.
  6. “Circulation of Antibiotics: Journeys of Drug Standards, 1930–1970.” Papers presented from June 16–18, 2009, Madrid, Spain. European Science Foundation, Centro de Ciencias Humanas y Sociales Consejo Superior de Investigaciones Científicas (CSIC). Romero, Ana Christoph Gradmann, and Maria Santemases, eds. (Oslo, Norway, May 2010).
  7. “Competitive Problems of the Drug Industry, Summary and Analysis.” Subcommittee on Monopoly, Prepared by the Congressional Research Service, Select Committee on Small Business, 90th and 91st Cong. (Washington, D.C.: Library of Congress, November 1972).
  8. “The Competitive Status of the U.S. Pharmaceutical Industry: The Influences of Technology in Determining International Industrial Competitive Advantage.” Edwards, Charles C., chairman.
  9. Control of Psychotoxic Drugs: Hearing Before the Subcommittee on Health of the Committee on Labor and Public Welfare, U.S. Senate, 88th Cong., 2nd sess., on S. 2628, a bill to protect the public health (August 3, 1964).
  10. “Declaration of Montréal: Declaration That Access to Pain Management Is a Fundamental Human Right.” International Pain Summit of the International Association for the Study of Pain. Journal of Pain and Palliative Care Pharmacotherapy 25, no. 1 (2011): 29–31.
  11. Department of Health, Education, and Welfare, FDA. “Report Including Recommended Findings and Conclusions re: Potential for Abuse of the Drugs Librium and Val-ium.” April 7, 1967, Manufacturers Files No. AF14–324, re Hoffmann-La Roche, Federal Drug Administration History Office.
  12. Final accounting by the executors of the decedent’s estate, Matter of Sackler, 0249220/2007 (September 28, 2007).
  13. Follow the Money: Pharmaceutical Manufacturer Payments and Opioid Prescribing Patterns in New York State. New York State Health Foundation Publication, June 2018.
  14. GAO report number GAO-03–177, “Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations.” Released December 04, 2002.
  15. Generic Drug Enforcement and Approval Process: Hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, 102nd Cong., 1st sess., March 7 and June 5, 1991.
  16. Hoffmann-La Roche, Inc., Petitioner, v. Richard G. Kleindienst, Attorney General of the United States, and John E. Ingersoll, Director, Bureau of Narcotics and Dangerous Drugs, United States Department of Justice, Respondents, 478 F.2d 1 (3d Cir. 1973), U.S. Court of Appeals for the Third Circuit—478 F.2d 1 (3d Cir. 1973), Argued June 25, 1971. Decided March 28, 1973, as Amended July 3, 1973.
  17. Impact of Direct-to-Consumer Drug Advertising on Seniors’ Health and Health-Care Costs: Hearing before the Special Committee on Aging, United States Senate, 109th Cong., 1st sess., Washington, D.C., September 25, 2004.
  18. Institute of Medicine (US) Forum on Microbial Threats. “Microbial Evolution and Co-Adaptation: A Tribute to the Life and Scientific Legacies of Joshua Lederberg.” Workshop Summary. (Washington, DC: National Academies Press, 2009).
  19. Lacy Glenn Thomas, Rapporteur, Prepared by the Pharmaceutical Panel, Committee on Technology and International Economic and Trade Issues, Office of the Foreign Secretary, National Academy of Engineering Commission on Engineering and Technical Systems, National Research Council (Washington, D.C.: National Academies Press, 1983).
  20. Medina, Jose L., and Seymour Diamond. “Drug Dependency in Patients with Chronic Headaches.” Headache, March 1977.
  21. Memoranda of Philip and Mary Jane Keeney, “FBI Silvermaster File 65–56402,” serial 2127; Testimony of Philip O. Keeney and Mary Jane Keeney and Statement Regarding Their Background: Hearings. U.S. House Committee on Un-American Activities (Washington, D.C.: U.S. Government Printing Office, 1949).
  22. Memorandum from Dr. A. M. Sackler to Dr. Félix Martí-Ibáñez, December 14, 1956, “Subj: Geography and World Patterns of Schizophrenia and Other Mental Illnesses,” MS 1235, Box 2, Folder “S” 1957, Papers of Félix Martí-Ibáñez, Yale University, Manuscripts and Archives, New Haven, CT.
  23. Napp Pharmaceutical Holdings Limited and Subsidiaries v. Director General of Fair Trading, In the Competition Commission, Appeal Tribunal, Before Sir Christopher Bellamy, Professor Peter Grinyer, and Harry Colgate, New Court, London, Case No 1001/1/01, January 15, 2002.
  24. Plea Agreement dated November 1, 2002, between the Office of the Attorney General, Department of Legal Affairs, State of Florida, and Purdue Pharma L. P. and Purdue Frederick Company, 9 pages, and Exhibits A and B and a 3-page amendment dated April 25, 2003.
  25. “Prescription Drug Advertising to Consumers,” Staff Report Prepared for the Use of the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce,” House of Representatives, 98th Cong., 2nd sess. (Washington, D.C.: U.S. Government Printing Office, September 1984).
  26. “Prescription Drugs: OxyContin Abuse and Diversion Efforts to Address the Problem.” General Accounting Office. (Washington, D.C.: U.S. Government Printing Office, December 2003).
  27. Present Status of Competition in the Pharmaceutical Industry, Part 30 of the Competitive Problems in the Drug Industry Hearings Before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, United States Senate, 94th Cong., 2nd sess., April 28, May 10 and 24, 1976.
  28. Proceedings of the Seventh Annual Convention of the National Association of State Dairy and Food Departments Held at St. Paul, Minnesota, Containing Proceedings of the Seventh Annual Convention. The Dairy and Food Laws of All the States and Territories with State and United States Supreme Court Decisions Thereon. Also Rulings and Tables of Standards Adopted by the State and Government Commissions. Published Under the Personal Direction of the National Association of State Dairy and Food Departments II. B. Meyers, Editor and Compiler, 1903.
  29. Public Hearings on Noise Abatement and Control, vol. VII—Physiological and Psychological Effects, October 28–29, 1971, conducted by the Office of Noise Abatement and Control, January 1, 1972.
  30. “The Rate of Addiction by Pain Patients Who Are Treated by Doctors, Is Much Less Than 1 Percent.” “I Got My Life Back.” Purdue Pharma L. P., video presentation by Dr. Alan Spanos, 1998.
  31. Records of the U.S. Senate, Committee on the Judiciary, Subcommittee on Antitrust and Monopoly, 86th and 87th Cong., RG 46.15, sub 13.115, NARA.
  32. See Matter of Estate of Sackler, 149 Misc.2d 734, 564 N.Y.S.2d 977, 980 (N.Y. Sur. Ct. 1990); Matter of Sackler, (September 28, 2007), 2007 NY Slip Op 33226(U) (N.Y. Misc. 2007).
  33. OxyContin: Balancing Risks and Benefits. Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, 107th Cong., 2nd sess., “On Examining the Effects of the Painkiller OxyContin, Focusing on Federal, State and Local Efforts to Decrease Abuse and Misuse of This Product While Assuring Availability for Patients Who Suffer Daily from Chronic Moderate to Severe Pain,” February 12, 2002. Printed for the use of the Committee on Health, Education, Labor, and Pensions, 77–770, U.S. Government Printing Office.
  34. Senate Judiciary Subcommittee on Antitrust and Monopoly Hearings, Part 6, Advertising Provisions, January 30, 1962.
  35. “Subcommittee on Reorganization and International Organizations of the Committee on Government Operations, U.S. Senate, 88th Cong., 1st sess., Agency Coordination Study, (Pursuant to S. Res. 27, 88th Cong., as Amended),” Review of Cooperation on Drug Policies Among the Food and Drug Administration, National Institutes of Health, Veterans’ Administration, and Other Agencies, March 20-June 26, 1963; Hearings Before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, U.S. Senate, 90th through 93rd Cong., 1967–1975.
  36. United States Attorney’s Office Western District of Virginia [news release]. Available at: http://www.dodig.osd.mil/IGInformation/IGInformationReleases/prudue_frederick_1.pdf.
  37. Use and Misuse of Benzodiazepines: Hearing Before the Subcommittee on Health and Scientific Research of the Committee on Labor and Human Resources, United States Senate, 96th Cong., 1st sess., September 10, 1979.
  38. U.S. Congress: Senate: Treatment and Rehabilitation of Juvenile Drug Addicts. Subcommittee to Investigate Juvenile Delinquency, Committee on the Judiciary. Hearings, pursuant to S.R. 173 and S.R. 303, December 1956, 984: 2, Washington, D.C., 1957.
  39. U.S. House, Committee on Government Operations, Subcommittee on Legal and Marketing Affairs (1958).
  40. U.S. Senate, Committee on Government Operations, Subcommittee on Reorganization and International Organizations, Interagency Coordination in Drug Research and Regulation (Washington, D.C.: U.S. Government Printing Office, 1964), 1.
  41. U.S. v. Chas. Pfizer & Co., et al. Defendants, United States District Court, Southern District New York, 245 F. Supp. 801 (1965), September 9, 1965.
  42. U.S. v. Chas. Pfizer & Co., et al. Defendants, United States District Court, Southern District New York, 367 F. Supp. 91 (1973), No. 61 Cr. 772, November 30, 1973.
  43. WHO Expert Committee on Addiction-Producing Drugs. Thirteenth report. Geneva, World Health Organization, 1964 (WHO Technical Report Series, No. 273); The ICD-10 Classification of Mental and Behavioral Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1992; WHO Expert Committee on Drug Dependence. Twenty-Eighth report. Geneva, World Health Organization, 1993 (WHO Technical Report Series, No. 836).
  44. World Health Organization, International Task Force on World Health Manpower & Symposium on Advances in the Drug Therapy of Mental Illness (November 21–23, 1973, Geneva).

Unpublished Manuscripts and Papers

  1. Mc-Crea, Frances B. “Politics and Medicine in the Estrogen Replacement Controversy: A Comparative Analysis of the United States and Great Britain.” Master’s Thesis, Graduate College of Western Michigan University, August 1981.
  2. Skolek Perez, Marianne. “You Messed with the Wrong Mother: One Mother’s 17-Year Personal Account Exposing Purdue Pharma, Maker of Oxy-Contin in Fueling the ‘Manufactured’ Opioid Epidemic Crippling the U.S.” Unpublished manuscript last modified October 2019. Cited here by courtesy of the author.